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ABSTRACT OF DISSERTATION

DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND
THE EFFECTS OF METHYLPHENIDATE TREATMENT
The prefrontal cortex (PFC) is an area of the brain that is critically
important for learning, memory, organization, and integration, and PFC
dysfunction has been associated with pathologies including Alzheimer’s disease,
schizophrenia, and drug addiction.
However, there exists a paucity of
information regarding neurochemical signaling in the distinct sub-regions of the
PFC, particularly the medial prefrontal cortex (mPFC). The mPFC receives
glutamatergic input from a number of brain areas, and functional glutamate
signaling is essential for normal cognitive processes. To further understand
glutamate neurotransmission, in vivo measurements of glutamate were
performed in the cingulate cortex, prelimbic cortex, and infralimbic cortex of
anesthetized rats using enzyme-based microelectrode array technology.
Measurements of acetylcholine were also performed to examine the relationship
between glutamate and other neurotransmitters in the mPFC. The described
studies revealed a homogeneity of glutamate and acetylcholine signaling in the
mPFC sub-regions, indicating somewhat uniform tonic and phasic levels of these
two transmitters. In the infralimbic mPFC of awake freely-moving rats, rapid,
phasic glutamate signaling events, termed “transients” were observed and in vivo
glutamate signaling was successfully monitored over 24 hour time periods.
The effects of methylphenidate (MPH), a stimulant medication with abuse
potential that is used in the treatment of attention-deficit hyperactivity disorder,
were measured in mPFC sub-regions of anesthetized rats. Data revealed similar
tonic and phasic glutamate levels between chronic MPH-treated rats and controls
in all sub-regions. Locomotor data from the chronic treatment period supported
the behavioral sensitization effects of multiple MPH treatments. Significant
effects were observed in locomotor activity, resting levels of glutamate, and
glutamate uptake rates in the infralimbic mPFC of awake, freely-moving animals
that received chronic MPH treatment.

Taken together, this body of work characterizes glutamate signaling in the
rat mPFC to a degree never before reported, and serves to report for the first
time the effects of MPH on glutamate signaling in the mPFC.
KEYWORDS: glutamate, prefrontal cortex, microelectrode array,
methylphenidate
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Chapter One: Introduction

The Functions and Anatomy of the Prefrontal Cortex
The term ‘prefrontal cortex’ was first used by Hines (Hines 1929) to
describe the area of the human brain anterior to the premotor cortex, and the
prefrontal area has been defined as the cortex “anterior to the arcuate sulcus on
the lateral, medial, and ventral surfaces of the frontal lobe,”(Walker 1940). In the
human brain, the PFC encompasses Brodmann’s areas 9/46 (dorsolateral PFC)
(Brodmann 1909; Rajkowska and Goldman-Rakic 1995) and 10 (rostral PFC)
(Brodmann 1909; Semendeferi, Armstrong et al. 2001), as well as parts of other
areas. The human medial prefrontal cortex (mPFC) is specifically composed of
areas 25, 32, and 10 (Ongur and Price 2000). The monkey brain has similar
boundaries, with the only difference being in the definition of Brodmann’s area
32. In rats, cytoarchitectural differences make it difficult to assign comparable
mPFC Brodmann’s areas, and thus areas of the rat brain are demarcated by their
connections with other brain structures (Rose and Woolsey 1948). It has been
argued that the mPFC does not exist in the brains of mammals other than
primates, (Preuss 1995), but within the neuroscience field, the overwhelming
amount of literature and research support the hypothesis that rats possess a
structure analogous to the primate mPFC (Kolb 1984; Heidbreder and
Groenewegen 2003; Uylings, Groenewegen et al. 2003; Seamans, Lapish et al.
2008).
As a brain structure that is involved in many global functions, the
prefrontal cortex (PFC) has long been an area of interest for neuroscientists.
The PFC has been shown to be critical for higher cognitive processes including
attention, memory, learning, decision making, and integration. However, many of
these processes are interrupted or dysfunctional in pathologies such as
Alzheimer’s disease, schizophrenia, and drug addiction.
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Dating back to the mid-twentieth century, studies by Jansen and
colleagues found that electrical stimulation of the prefrontal cortex in cats
resulted in “searching” and “attention” responses (Jansen, Andersen et al. 1955).
Neurons in the prefrontal cortex of monkeys have been shown to have increased
activation during an attentional task (Suzuki and Azuma 1977)
The PFC has been shown to be necessary for certain memory processes,
specifically working memory. Lesions of the PFC have been demonstrated to
drastically impair working memory performance in matching-to-sample tasks
(Winocur 1992; Granon, Vidal et al. 1994), avoidance tasks (Fritts, Asbury et al.
1998), and visual object discrimination (Ragozzino, Detrick et al. 2002).
Additionally, antagonism of the PFC glutamatergic system has been shown to
impair spatial working memory performance (Jentsch, Tran et al. 1997) and
human fMRI studies suggest that PFC neural activity is responsible for
maintaining working memory and attention (Rypma and D'Esposito 1999; Hartley
and Speer 2000; Osaka, Komori et al. 2007; Ikkai and Curtis 2011). Learning
also involves the PFC, as illustrated in studies with non-human primates (Wise,
Murray et al. 1996; Asaad, Rainer et al. 1998; Toni and Passingham 1999;
Pasupathy and Miller 2005). Specifically, PFC neurons have been shown to be
most strongly activated when cues are changed during a task (Asaad, Rainer et
al. 1998), and the PFC has been implicated in learning a visuomotor conditional
task during PET scans in non-human primates (Toni and Passingham 1999).
PFC neuronal activity during a trial has also been shown to be dependent on the
outcome of a previous trial (Histed, Pasupathy et al. 2009).
Decision making is another example of a PFC integration process, as
decision making involves evaluating material, predicting outcomes, and then
making a choice. In patients with frontal damage, novel choices are difficult
(Godefroy and Rousseaux 1997), and decisions may be made with only
immediate outcomes in mind (Bechara, Tranel et al. 2000; Manes, Sahakian et
al. 2002). Studies using neuroimaging techniques during decision making tasks
also implicate the PFC in the decision making process (Paulus, Hozack et al.
2002; Heekeren, Wartenburger et al. 2003; Rogers, Ramnani et al. 2004).
2

The mPFC has been implicated in the development and maintenance of
drug addiction.

Lesions of the mPFC have been shown to decrease lever

pressing for cocaine in rats (Goeders and Smith 1986) as well as eliminate
cocaine-induced sensitization (Li, Hu et al. 1999), and neuronal firing between
the mPFC and nucleus accumbens, a structure in the brain involved in drug
addiction, has been shown to be correlated just prior to the self-administration of
cocaine (Chang, Janak et al. 2000). Withdrawl from amphetamines has been
shown to alter glutamate receptor expression in the mPFC (Lu, Monteggia et al.
1999), and mPFC glutamate levels have been shown to increase following a
cocaine challenge dose after a withdrawl period in rats previously treated with
cocaine (Williams and Steketee 2004). Together, these data indicate that the
mPFC at least plays some role in stimulant drug abuse.
The connections of the PFC are many and of differing modalities. The
defining characteristic of the PFC is the projection it receives from the
mediodorsal nucleus of the thalamus (Leonard 1969; Krettek and Price 1977;
Divac, Kosmal et al. 1978; Groenewegen 1988). This projection is glutamatergic
in nature, and the mPFC sends a reciprocal glutamatergic efferent to the
mediodorsal nucleus as well (Pirot, Jay et al. 1994). Glutamatergic afferents
arise from limbic structures such as the amygdala (Bacon, Headlam et al. 1996;
McDonald 1996) and the hippocampus (Jay, Thierry et al. 1992), and these
structures also receive reciprocal glutamatergic efferents from the mPFC. Within
the mPFC, glutamatergic recurrent collaterals from pyramidal neurons synapse
on each other (Pirot, Glowinski et al. 1995). The mPFC sends glutamatergic
projections to a variety of brain regions including the nucleus accumbens (NAc)
(Christie, James et al. 1985), periaqueductal grey matter (Christie, James et al.
1986), ventral tegmental area (VTA) (Taber, Das et al. 1995; Rossetti,
Marcangione et al. 1998), and striatum (Karreman and Moghaddam 1996). A
second neurotransmitter system, the dopaminergic system, is intimately related
to the glutamatergic system in the mPFC. The mPFC receives dopaminergic
projections from the VTA (Thierry, Blanc et al. 1973; Lindvall, Bjorklund et al.
1978) that serve to modulate mPFC pyramidal neuronal excitability (Gulledge
3

and Jaffe 2001). The mPFC can also indirectly influence the NAc (Ungerstedt
1971; Beckstead, Domesick et al. 1979), hippocampus (Gasbarri, Verney et al.
1994; Gasbarri, Sulli et al. 1997), and amygdala (Oades and Halliday 1987) via
dopaminergic projections from the VTA (for a diagram of the mPFC/limbic system
connections, see Figure 1.1). The neurotransmitter γ-aminobutyric acid (GABA)
serves to modulate the mPFC as well. GABA in the mPFC arises from local
circuit neurons within the mPFC (Retaux, Julien et al. 1992), as well as from VTA
projections to the mPFC (Pirot, Godbout et al. 1992; Carr and Sesack 2000). For
the purposes of this thesis, the glutamatergic system is the main focus.

Glutamate Regulation
Glutamate, an amino acid, is the major excitatory neurotransmitter of the
central nervous system. Glutamate was first suggested as a neurotransmitter by
Hayashi in 1954 (Hayashi 1954), and later confirmed through identification of
glutamate receptors and specific antagonists (Davies, Evans et al. 1979; Watkins
and Evans 1981).
Glutamate signaling involves multiple receptors, transporters, and neurons
as well as glia (representative synapse is diagrammed in Figure 1.2). Glutamate
is synthesized in two ways in the brain. Glutamate can be created from glucose
via the Krebs cycle, and glutamate can be synthesized via the glutamateglutamine cycle.

Glutamine, a precursor for glutamate synthesis, is readily

available in extracellular fluid (Hamberger and Nystrom 1984; Fonnum 1993).
Glutamine is transported into the presynaptic neuron via low affinity transport
(Erecinska and Silver 1990) and is converted to glutamate via phosphate
activated glutaminase, an enzyme that is localized to the mitochondria (Laake,
Takumi et al. 1999).

Intracellular glutamate is then packaged into synaptic

vesicles by a v-type proton-pump ATPase and a vesicular glutamate transporter
(VGLUT) (Lewis and Ueda 1998; Bellocchio, Reimer et al. 2000).

Calcium-

triggered exocytosis allows for the delivery of glutamate from the vesicle into the
synaptic cleft. It is important to note that glutamate may also enter the synapse
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through calcium-dependent vesicular release from astrocytes (Montana, Ni et al.
2004) or through the actions of the cystine-glutamate exchanger, found on glia
(Baker, Xi et al. 2002).
Once in the synaptic cleft, glutamate can act on two different types of
receptors: ionotropic glutamate receptors and metabotropic glutamate receptors.
Ionotropic glutamate receptors include N-methyl-D-aspartate (NMDA) receptors,
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, and
kainate receptors (Watkins and Evans 1981) (see Table 1.1 for review). These
receptors are all glutamate gated ion channels that conduct Na+ and K+, with
NMDA receptors also being permeable to Ca2+ (Mayer and Westbrook 1987;
Ascher and Nowak 1988). The AMPA and kainate receptors are responsible for
voltage-independent fast signaling, and are often grouped together as nonNMDA receptors due to their similar responses to glutamate receptor agonists
and antagonists (Bettler and Mulle 1995).

These non-NMDA receptors also

desensitize quickly (Trussell and Fischbach 1989). NMDA receptors, however,
are slower to desensitize, and their signaling results in slower changes in
postsynaptic current (Collingridge, Herron et al. 1988; Hestrin, Nicoll et al. 1990;
Lester, Clements et al. 1990). Additionally, NMDA receptors require membrane
depolarization to remove the Mg2+ block that inhibits ion channel permeability
(MacDonald and Wojtowicz 1982; Mayer and Westbrook 1985; Flatman,
Schwindt et al. 1986).
Metabotropic glutamate receptors (mGluRs) are G-protein coupled
receptors with seven transmembrane domains. These receptors signal slower
due to their protein coupling, and are classified into three groups.

Group I

mGluRs consist of mGluR1 and mGluR5, group II includes mGluR2 and mGluR3,
and group III is associated with mGluR4, mGluR6, mGluR7, and mGluR8. The
groups differ by their methods of signal transduction and their responses to
agonists (see Table 1.2 for review). Together, the ionotropic and metabotropic
glutamate receptors are essential for glutamate signal transduction.
Glutamate signaling is tightly regulated within the brain, and glutamate
uptake is a critically important process for preventing excitotoxicity associated
5

with excess glutamate. Glutamate is cleared from the synapse by high affinity
sodium-dependent excitatory amino acid transporters (EAATs).

Five EAATs

have been identified to date: GLAST (EAAT1), GLT-1 (EAAT2), EAAC (EAAT3),
EAAT4, and EAAT5. GLAST and GLT-1, are localized to astrocytes (Storck,
Schulte et al. 1992) (Pines, Danbolt et al. 1992; Rothstein, Martin et al. 1994;
Chaudhry, Lehre et al. 1995), while EAAC is localized to neurons (Kanai and
Hediger 1992; Rothstein, Martin et al. 1994). EAAT4 is localized to Purkinje cells
in the cerebellum (Furuta, Rothstein et al. 1997), and EAAT5 is localized to the
retina (Pow and Barnett 2000). GLAST and GLT-1 are responsible for glutamate
uptake into glia.

Once in the glia, glutamate is converted to glutamine by

glutamine synthase, and the resulting glutamine is released into the extracellular
space to continue the cycle.

Methylphenidate and Alterations in Glutamate Neurotransmission
Drug abuse is a problem that has plagued humanity for as long as
recorded history. In the United States in 2010, the Substance Abuse and Mental
Health Services Administration estimated 23 million Americans had used an illicit
substance within the month prior to data collection (approximately 8.9 percent of
the population) (2011).

Alarmingly, in 2011, 50% of high school students

reported using an illicit drug by the time they left high school (Johnston and
Schulenberg 2012). Illicit drug use has been shown to be associated with risky
behaviors, including unprotected sex (DeHovitz, Kelly et al. 1994; Diaz, Chu et al.
1994; Hwang, Ross et al. 2000) and criminal activity (Mumola 1999; Friedman,
Glassman et al. 2001). A 2009 study by the National Highway Traffic Safety
Administration found 18% of fatally injured drivers tested positive for at least one
substance (2010).

Illicit drug use was also associated with almost one million

emergency department visits in the U.S. in 2009, and the percentage of
pharmaceutical misuse or abuse emergency department visits increased 98%
from 2004 to 2009 (2010). The costs associated with drug abuse totaled $140
billion in 1998, with the majority of the costs associated with lost productivity
6

(2001). Without a better understanding of brain changes associated with drug
abuse and potential treatments, these costs will continue to climb as our
population increases.
One drug with abuse potential that has gained popularity relatively
recently is methylphenidate (MPH; Ritalin), a stimulant that was first synthesized
in 1944.

In the brain, the mechanism of action for MPH is similar to other

stimulants. MPH binds with high affinity to the dopamine transporter (Ritz, Lamb
et al. 1987; Heron, Costentin et al. 1994; Pan, Gatley et al. 1994; Wayment,
Deutsch et al. 1999), and thus inhibits presynaptic reuptake of dopamine,
allowing for increased concentrations of this neurotransmitter in the extracellular
space (Hurd and Ungerstedt 1989; Butcher, Liptrot et al. 1991). This increase in
extracellular dopamine concentration is responsible for the stimulant effects of
the drug (Taylor and Snyder 1971; Roberts, Zis et al. 1975). MPH exerts indirect
influence over dopamingergic signaling through the vesicular monoamine
transporter -2 (VMAT-2).

MPH has been shown to increase intracellular

dopamine uptake into vesicles (Sandoval, Riddle et al. 2002), and redistribute
VMAT-2 from synaptosomal membranes into the cytoplasm (Volz, Farnsworth et
al. 2008). Increases in norepinephrine (NE) release have also been observed
following MPH administration, as MPH acts on the norepinephrine transporter
(Wall, Gu et al. 1995; Gatley, Pan et al. 1996).

MPH differs from other

stimulants, such as amphetamine, in that it has no effect on the serotonergic
system (Kuczenski and Segal 1997).
The primary use of MPH is as a medication that is prescribed for the
treatment of attention-deficit hyperactivity disorder (ADHD) (Sykes, Douglas et al.
1972; Porges, Walter et al. 1975; Charles, Schain et al. 1981).

Although it

seems counterintuitive to treat ADHD with a stimulant medication, low-level
stimulant treatment has been shown to improve cognitive performance in both
non-ADHD and ADHD-diagnosed children and adolescents (Gabrys 1977; Mohs,
Tinklenberg et al. 1978; Rapoport, Buchsbaum et al. 1978; Balthazor, Wagner et
al. 1991; Klein 1993; Gimpel, Collett et al. 2005). MPH is a schedule II controlled
substance in the U.S. In 2010, approximately 1.9 million children received MPH
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prescriptions (Chai, Governale et al. 2012), and it has been estimated that 5-15%
of children and adolescents in the U.S. are taking MPH (Barbaresi, Katusic et al.
2002).

MPH is typically taken orally (although transdermal patches are an

option), and is available in immediate and extended release formulations. The
standard treatment dose averages up to 1.0 mg/kg, although this varies among
individuals (Greenhill, Abikoff et al. 1996), and MPH peak plasma concentrations
appear roughly two hours after an oral dose is taken (Wargin, Patrick et al.
1983). MPH is generally accepted as one of the preferred treatments for ADHD
(Wigal 2009; De Sousa and Kalra 2012).
However, there is some evidence that ADHD is over diagnosed (Meijer,
Faber et al. 2009; Bruchmuller, Margraf et al. 2012; Morrow, Garland et al. 2012),
thus contributing to an increase MPH and other ADHD stimulant medication
prescriptions (Safer, Zito et al. 1996; Olfson, Gameroff et al. 2003). This is a
problem, as misdiagnoses could lead to unnecessary exposure to stimulant –
based pharmacotherapies, especially in children and adolescents. It has been
shown that MPH serves as a reinforcer for children diagnosed with ADHD
(MacDonald Fredericks and Kollins 2005), and animal studies have also
established the reinforcing effects of MPH (Collins, Weeks et al. 1984; Nielsen,
Duda et al. 1984).

Rats will self-administer MPH (Botly, Burton et al. 2008;

Marusich and Bardo 2009; Marusich, Beckmann et al. 2010), and rats exposed to
MPH during adolescence adapt readily to cocaine self-administration as adults
(Brandon, Marinelli et al. 2001; Crawford, Baella et al. 2011; Harvey, Sen et al.
2011). These experiments help to illustrate the serious abuse potential of MPH
and highlight the importance of carefully considered ADHD diagnoses.
Additionally, the physiological side effects of stimulant treatment can be serious.
MPH is associated with minor increases in blood pressure and heart rate (Stiefel
and Besag 2010), long term treatment has been shown to stunt physical height in
children (Zhang, Du et al. 2010) and sleep disturbances are often reported
(Greenhill, Puig-Antich et al. 1983; Corkum, Panton et al. 2008).
MPH abuse has been on the increase in college and adolescent
populations in recent years (DeSantis, Webb et al. 2008; Dupont, Coleman et al.
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2008; Bogle and Smith 2009; Setlik, Bond et al. 2009). MPH is abused in the
college population, often as a “study drug” (Sussman, Pentz et al. 2006; Teter,
McCabe et al. 2006).

In animal studies, MPH has been shown to increase

extracellular dopamine in the PFC in rat studies (Bymaster, Katner et al. 2002).
Additionally, given the increased use of MPH in recent years, both legal and illicit,
a greater understanding of the effects of MPH on neurochemical signaling is
warranted.
Although many neurotransmitter systems have been implicated in the
development of drug abuse and addiction, the actions of the glutamate system
warrant further investigation due to the amount of glutamate signaling that occurs
in the brain.

Previous studies have linked alterations in glutamate

neurotransmission with abuse of substances including cocaine (Pulvirenti,
Swerdlow et al. 1989; Pulvirenti, Swerdlow et al. 1991; Witkin 1993),
amphetamine (Pulvirenti, Swerdlow et al. 1989; Kelley and Throne 1992),
methamphetamine (Hara, Akaike et al. 1987; Earle and Davies 1991; Witkin
1993), heroin (Pulvirenti, Swerdlow et al. 1991; Xi and Stein 2002), phencyclidine
(Idriss and Albuquerque 1985; Loo, Braunwalder et al. 1987), and alcohol (Freed
and Michaelis 1978; Michaelis, Michaelis et al. 1980; Ledig, M'Paria et al. 1982).
In light of the fact that glutamate is responsible for some of the signaling within
the reward circuitry in the brain, glutamate likely plays a role in the development
and maintenance of addiction. As previously described, the mPFC maintains
connections with the mesolimbic dopamine system, which is implicated in the
reward circuitry of addiction.
Despite the amount of literature in the area of drug addiction research,
MPH’s effects on the glutamate system are not yet well understood. However,
other stimulants have been reported to increase glutamate levels in the PFC
(Reid, Hsu et al. 1997). In the studies detailed in this dissertation, the effects of
MPH on the glutamate system in the mPFC were explored using an advanced
neurochemical monitoring technique, the microelectrode array.

9

Microelectrode Array Measurements of Glutamate
Neurotransmission
The ability to accurately measure in vivo levels of neurotransmitters has
long been a topic of interest in the field of neuroscience. Microdialysis has been
the preferred method for measuring neurochemistry since the early 1980s
(Zetterstrom, Sharp et al. 1983; Benveniste and Huttemeier 1990). Until recently,
microdialysis was unchallenged as the gold standard technique for measuring in
vivo levels of neurotransmitters in the mammalian central nervous system, and
the majority of what is known about mPFC glutamate and levels comes from
microdialysis studies. However, microdialysis is limited in two critical areas 1) by
its temporal resolution (minutes) (Nandi and Lunte, 2009) and 2) by its spatial
resolution (millimeters) (Clapp-Lilly et al., 1999). Furthermore it has been shown
to cause extensive brain damage (millimeters) around the probe (Clapp-Lilly et
al., 1999; Georgieva et al., 1993; Grabb et al., 1998).
Our group has worked extensively on a microelectrode array (MEA)
technology that allows for measurements of neurotransmitter synaptic spillover at
rates of 1-4 Hz. With platinum recording sites having a small footprint (15 x 333
µm) and measuring neurotransmitters in the nanomolar range, the MEAs allow
for the characterization of specific brain sub-regions, such as those in the
prefrontal cortex (Bruno et al., 2006; Burmeister et al., 2008; Day et al., 2006;
Nickell et al., 2005; Stephens et al., 2009). Additionally, the multiple Pt recording
sites of the MEA allow for a self-referencing technique that subtracts background
current and provides in vivo measurements of glutamate concentration. MEAs
can readily be used in anesthetized or awake experiments, allowing for
measurements

of

neurochemistry

in

multiple

brain

regions,

or

while

simultaneously monitoring animal behavior.
The advanced spatial and temporal resolution of MEA technology has
allowed us to characterize mPFC sub-regional glutamate neurotransmission to a
degree never before reported.

Additionally, we have been able to use this

technique to examine the effects of MPH on the glutamate system, observe
dynamic changes in phasic glutamate signaling, and measure tonic glutamate
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levels during awake freely-moving animal experiments. The information gained
from these experiments will help the neuroscience field to better understand the
role of glutamate in the mPFC in drug addiction.

Portions of this chapter have been previously published in the manuscript:
Mattinson, C.E., Burmeister, J.J., Quintero, J., Pomerleau, F., Huettl, P.,
Gerhardt, G.A. 2011. Tonic and phasic release of glutamate and
acetylcholine neurotransmission in sub-regions of the rat prefrontal cortex
using enzyme based microelectrode arrays. J Neurosci Methods. 202 (2):
199-208.
Permission was obtained from Elsevier for use.
Copyright © Catherine Elizabeth Mattinson 2012
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the NMDA receptor or AMPA/KA receptors. Glutamate can also be taken up into
the postsynaptic neuron by the excitatory amino acid transporter EAAC. On the
glia, glutamate can be cleared from the synapse by the excitatory amino acid
transmitters GLT-1 and GLAST. Glia also possess mGluRs, and glutamate can
be returned to the synapse via the actions of the glutamate/cysteine exchanger.
Within the glia, glutamate is converted to glutamine via glutamine synthetase.
Glutamine diffuses in the extracellular space, and is taken up by presynaptic
neurons for further use. Figure adapted from (Schoepp 2001).
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Table 1.1: Characteristics of Ionotropic Glutamate Receptors
Ionotropic Glutamate Receptors
NMDA
AMPA
Kainate
NMDA
AMPA
Kainic acid
Receptor
Selective
Agonists
Ibotenate
Quisqualic acid
Domoic acid
Other Agonists
Quinolinate
L-aspartate
Homocysteate
D-AP5
CNQX
CNQX
Receptor
D-AP7
DNQX
DNQX
Selective
CGS-19755
Antagonists
CGP-37849
CGP-40116
CPP
CGS 19755
NBQX
Other
GYK1 52466
Antagonists
MK-801
Channel
Phencyclidine
Blockers
Ionotropic glutamate receptors are divided into three types, based on their
interactions with specific small signaling molecules. The discussion of agonist
and antagonists is made more complicated by the glutamate and glycine binding
sites on NMDA receptors, thus only the glutamate binding sites are described in
this table. Abbreviations: NMDA, N-methyl-D-aspartate; D-AP5, (R)-2-amino-5phosphonopentanoate; D-AP7, amino-7 phosphonoheptanoic acid; CGS-19755,
(±)-cis-4-phosphonomethyl-2-piperidine carboxylic acid; CPP, 3-(2carboxypiperazin-4-yl)-propyl-1-phosphonic acid; MK-801, dizocilpine; AMPA, αamino-3-hydroxy-5-methyl-4-isoazolepropionic acid; CNQX, 6-cyano-7nitroquinoxaline-2,3-dione; DNQX, 6,7-dinitro-quinoxaline-2,3-dione; NBQX, 2,3dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline; GYK1 52466, 1-(4aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine. Adapted
from Cooper et al., 2003.
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Table 1.2: Characteristics of Metabotropic Glutamate Receptors
Receptor G Protein
Location
Agonists
and
Function
Postsynaptic
3,5-DHPG
G q;
Group
mGlu1
increased
neurons
quisqualate
I
PLC

Antagonists
CPCCOEt
LY367385
EMQMCM
JNJ16259685
YM298198
MPEP
MTEP
Fenobam
EGLU
LY341495
LY307452

Postsynaptic
G q;
increased
neurons, glia
PLC
Pre- and
DCG-IV
G i , G o;
Group
mGlu2
decreased
postsynaptic
APDC
II
AC
neurons
LY379268
LY354740
G i , G o;
Postsynaptic
mGlu3
LY404039
decreased
neurons, glia
LY389795
AC
G i , G o;
Pre- and
L-AP4
CPPG
mGlu4
Group
decreased
postsynaptic
L-SOP
MAP4
III
AC
neurons
PPG
G i , G o;
Retinal tissue
mGlu6
3,4-DCPG
decreased
dendrites
(mGlu8)
AC
G i , G o;
Pre- and
mGlu7
decreased
postsynaptic
AC
neurons
G i , G o;
Pre- and
mGlu8
decreased
postsynaptic
AC
neurons
Metabotropic glutamate receptors consist of eight different receptors that are
divided into three groups based on their characteristics. Abbreviations: PLC,
phospholipase C; AC, adenyl cyclase; 3,5-DHPG, 3,5-dihydroxyphenylglycine;
DCG-IV, (2S,2’R,3’R)-2-(2’,3’-dicarboxycyclopropyl)glycine; APDC, 2R,4R-4aminopyrrolidine-2,4-dicarboxylic acid; L-AP4, (S)-2-amino-4-phosphonobutanoic
acid; L-SOP, S-serine-O-phosphate PPG, (RS)-4-phosphonophenylglycine; 4,3DCPG, CPCCOEt, 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid
ethyl ester; EMQMCM, (3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)methanone methane sulfonate; MPEP, 2-methyl-6-(phenylethynyl)pyridine;
MTEP, 3-[2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; EGLU, (S)-α-ethylglutamic
acid; CPPG, (RS)-α-cyclopropyl-4-phosphonophenylglycine; MAP4, (S)-αmethyl-2-amino-4-phosphonobutanoic acid. Adapted from Schoepp, 2001.
mGlu5
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Thesis Outline
There exists a paucity of information in our current understanding of tonic
and phasic glutamate signaling in the mPFC, and thus not much is known about
how stimulant drug use affects glutamatergic signaling in this brain region. The
studies detailed in this dissertation sought to further explore and characterize
glutamate neurotransmission, and explore the effects of MPH on glutamate
signaling in the mPFC.

In Chapter Three, we investigated glutamate and

acetylcholine (ACh) dynamics in the cingulate, prelimbic, and infralimbic subregions

of

the

mPFC.

The

glutamatergic

and

acetylcholinergic

neurotransmission of the individual sub-regions of the mPFC has not been well
characterized in the literature, as microdialysis probe size is prohibitive for
measuring these distinct brain regions.

Our results revealed uniform resting

levels for each neurotransmitter among the three sub-regions.

KCl-evoked

release of glutamate and ACh resulted in similar peak amplitude concentrations
within each neurotransmitter among the sub-regions. However, comparison of
peak amplitudes and T80 values between glutamate and ACh revealed significant
differences. These data suggest an unexpected uniformity of both glutamate and
ACh signaling in the mPFC.
Chapter Four chronicles the characterization of glutamate signaling in the
infralimbic mPFC in the awake freely moving animal. We sought to identify and
measure rapid and dynamic changes in glutamate signaling termed glutamate
‘transients’. The infralimbic sub-region was identified as an area of interest due
to its multiple roles in higher cognitive processes, as well as the potential it has
for circadian influences.

24 hours recordings showed significant effects in

glutamate resting levels, transient glutamate events, and peak amplitude
concentrations.

Correlations were found between glutamate transients and

glutamate concentrations, as well as glutamate concentrations and locomotor
activity. These data confirm the presence of transients in the infralimbic mPFC,
and highlight relationships between glutamate signaling parameters during light
and dark cycle phases.
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The effects of MPH on glutamate signaling were explored in Chapter Five.
A depth profile analysis was performed through three sub-regions of the mPFC
following chronic treatment with MPH to identify any alterations in glutamate
signaling.

Rats chronically treated with MPH showed increased locomotor

activity during the treatment period as compared to saline controls. Data did not
reveal any significant differences in resting levels of glutamate among subregions or between treatment groups. Chronically MPH-treated animals trended
towards higher glutamate concentration than their saline counterparts.

KCl-

evoked glutamate release did not differ in peak amplitude, T80 values, or uptake
rates among sub-regions or between groups, but T80 values in the prelimbic and
infralimbic sub-regions of chronically MPH-treated rats tended to be increased as
compared to chronically saline-treated rats. These data indicate that MPH does
produce significant locomotor effects, and that MPH treatment did not
significantly alter glutamate neurotransmission.

However, the effects of

anesthetic are a possible confound, and further studies need to be performed in
awake-freely moving animals.
Chapter Six examines the effects of MPH treatment on infralimbic
glutamate neurotransmission in the awake freely-moving rat.

In addition to

avoiding the possible confounds of urethane anesthesia, unanesthetized
experiments allow for the simultaneous measurement of behavior and glutamate
signaling. Significant effects were found in locomotor activity from the chronic
treatment period, as well as during saline, MPH and cocaine challenge doses.
Significant effects were also seen in glutamate resting levels during these
challenge doses. These data support behavioral sensitization associated with
MPH administration, and indicate that infralimbic mPFC glutamate resting levels
may play a role in the reinforcing effects of chronic MPH treatment.
Chapter Seven serves to provide a summation of the results and
interpretations of this body of work. The findings from these experiments are
discussed and future experiments are suggested to continue to expand upon this
area of research.
Copyright © Catherine Elizabeth Mattinson 2012
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Chapter Two: Materials and Methods

Chemicals
Reagents were purchased from Sigma-Aldrich (St. Louis, MI), except
where noted.

Animals
Male Fischer 344 rats or male Sprague-Dawley rats were used for all
experiments (Harlan, Indianapolis, IN). The animals were given access to food
and water ad libitum, and were maintained on a 12 h light: 12 h dark cycle (lights
on at 06:00 h). Animals were individually housed, and were monitored by the
Department of Laboratory Animal Resources at the University of Kentucky. All
protocols were reviewed and approved by the Institutional Animal Care and Use
Committee.

Amperometry
Recordings were generated by applying a constant potential of +0.7 V vs.
a Ag/AgCl reference electrode to a microelectrode array. The potential allowed
for electroactive substances, such as the reporter molecule H2O2, to be oxidized
at the platinum recording sites on the microelectrode array. The resulting current
was digitized by a Fast Analytical Sensing Technology-16 mkII potentiostat
(FAST-16 mkII; Quanteon LLC, Nicholasville, KY) into a signal that could be
analyzed.

Microelectrode Array Configuration and Preparation

Microelectrode Array Fabrication
Microelectrode arrays were manufactured in conjunction with Thin Film
Technologies, Inc. (Buellton, CA), and a detailed description of the process is
available in previously published articles (Burmeister, Moxon et al. 2000;
Burmeister and Gerhardt 2001).

Briefly, a photomask was used to pattern
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electrodes onto ceramic wafers (Coors Ceramics Co., Golden, CO). Titanium
and platinum were sputter-coated onto the ceramic, and lift off revealed the
recording sites and connecting lines.

Ceramic electrodes were cut from the

wafers and bonded to printed circuit boards (Hybrid Circuits, Inc., Sunnyvale,
CA). Microelectrode surfaces, except for the recording sites, were insulated with
a polyimide coating to minimize cross-talk between the recording sites.

Microelectrode Array Site Configuration
The S-2 microelectrode pad configuration was used for all experiments.
The S-2 microelectrode array consists of four platinum recording sites, each
measuring 15 x 333 µm.

The sites are arranged two pairs, with 30 µm

separating the sites within a pair, and 100 µm separating the two pairs vertically.
The bottom pair of sites begins 100 µm from the tapered end of the ceramic tip.
This configuration is pictured in Figure 2.1.

Modifications for Awake Freely-Moving Recordings
For unanesthetized experiments, the microelectrode array circuit board
was modified to reduce the size of the implant. The process of fabricating this
type of microelectrode array has been previously described (Rutherford,
Pomerleau et al. 2007; Hascup, Hascup et al. 2008). Briefly, 30 gauge varnished
copper wire (Radioshack, Ft. Worth, TX) was cut into one inch long pieces. The
coating was removed approximately 1/8” in from either end. One end of the wire
was soldered into a small gold-plated socket (Ginder Scientific, Nepean, ON).
The other end of the wire was soldered to the “stub” type circuit board of the
microelectrode array.

After all four channels were soldered, the gold-plated

sockets were inserted into a black nine pin ABS plug (Ginder Scientific, Nepean,
ON). A miniaturized Ag/AgCl reference electrode was also inserted into the plug.
The wires were arranged so that they did not touch each other or solder. Loctite
Quickset Epoxy (Henkel Corp., Rocky Hill, CT) was used to cover and secure the
wires and electrode to the plug. The epoxy was allowed to cure for a minimum of
24 hours before microelectrode array implantation.
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Microelectrode Array Coatings
Microelectrode arrays were prescreened through a cleaning and
preliminary testing process to minimize inherent platinum recording site
differences.

Enzyme coatings (Figure 2.1) were used to make the

microelectrode arrays selective for and sensitive to glutamate. This process has
been described previously (Burmeister and Gerhardt 2001; Burmeister,
Pomerleau et al. 2002; Day, Pomerleau et al. 2006).

Glutamate detecting

microelectrode arrays were coated with a solution of 0.1 units/µL glutamate
oxidase, 1% bovine serum albumin (BSA), and 0.125% glutaraldehyde on one
pair of platinum recording sites, while the second pair of recording sites was
coated with only the BSA/glutaraldehyde coating matrix solution Three coats of
each solution were applied to their respective sites using 10 µl Hamilton syringes
(Hamilton Co., Reno, NV), with one minute of curing time allowed between each
coat. Microelectrode arrays cured at room temperature for a minimum of 48
hours before use.

Exclusion Layers
An exclusion layer was applied to the microelectrode surface to minimize
potential electroactive interferents, such as ascorbic acid, from coming into
contact with the platinum recording sites. Different exclusion layers were used
for anesthetized versus awake freely-moving recordings. In the anesthetized
preparation, a size exclusion layer of m-Phenylenediamine (mPD; 5 mM in 0.5 M
phosphate-buffered saline; Acros Organics, Geel, Belgium) was electrodeposited
on to the platinum recording sites prior to calibration. mPD excludes interferents
based on the size of the molecule, thus excluding ascorbic acid and allowing
H2O2 to reach the platinum recording sites.

In preparation for awake freely

moving experiments, Nafion®, a poly-sulfonated Teflon® derivative, was coated
onto microelectrode arrays by swirling the ceramic tip of the microelectrode in
Nafion® and then baking the microelectrodes for four minutes at 200˚C. Nafion®
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excludes interferents based on the charge of the molecule, and is generally
thought to be more stable for chronic in vivo measurements.

Microelectrode Array Calibrations
All microelectrode arrays were calibrated in vitro before implantation.
Microelectrode arrays with a Nafion® exclusion layer were soaked in phosphate
buffered saline (PBS) solution (0.05 M, pH = 7.4) for a minimum of 30 minutes
prior to calibration to activate the exclusion layer. PBS (40 mL) was added to a
50 mL beaker, and placed in a water bath maintained at 37˚C by a recirculating
pump (Gaymar Industries, Inc., Orchard Park, NY). A miniature stir bar was
added to the beaker, and the solution was stirred by a battery-operated, portable
magnetic stir plate (Barnant Co., Barrington, IL).

A glass Ag/AgCl reference

electrode (Bioanalytical Systems, West Lafayette, IN) and approximately half of
the ceramic tip of the MEA were lowered into the PBS. The calibration was
performed using FAST system software. During the calibration, ascorbic acid (20
mM; 500 µL) was added as an interferent, and three serial additions of glutamate
(20 mM; 40 µL) were added to establish the slope of the signal in response to
glutamate (Figure 2.2). Dopamine (2 mM; 40 µL) and H2O2 (8.8 mM; 40 µL)
were also used as a test substance and a positive control, respectively.
Parameters of interest included slope, limit of detection (LOD), linearity of the
response to the glutamate additions, and selectivity for glutamate over other
substances.

Reference Electrode Preparation
For in vivo experiments, a miniature Ag/AgCl reference electrode was
created using Teflon®-coated silver wire (A-M Systems, Inc., Sequim,
Washington, 0.008” bare, 0.011” coated). The wire was stripped approximately
1/8” from each of the ends. For anesthetized preparations, one end of the wire
was soldered into a gold pin amphenol (Mill-Max Mfg. Corp., Oyster Bay, NY).
For awake freely moving preparations, one end of the wire was soldered into a
gold-plated socket. The other end was placed in a 1 M HCl solution that was
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saturated with NaCl.

A platinum wire that served as the cathode was also

submerged in the plating bath. A nine-volt power supply (Elenco Inc., Wheeling,
IL) was used to anodize the silver wire for 15 minutes. After plating, the Ag/AgCl
reference electrode was stored in an amber bottle containing 3 M NaCl until use.

Application of Intracranial Solutions
For anesthetized experiments, a glass micropipette was affixed to the
microelectrode array to allow for pharmacological manipulation in vivo. A glass
micropipette (A-M Systems, Inc.; 1 mm o.d., 0.58 i.d.,) was pulled using a vertical
pipette puller (David Kopf Instruments, Tujunga, CA).

The micropipette was

bumped to an inner diameter of approximately 10 µm. Sticky wax (Kerr Corp.,
Orange, CA) was used to adhere the micropipette to the microelectrode array,
with the micropipette tip centered between the four platinum recording sites and
approximately 75 µm from the surface of the microelectrode array.

Microelectrode Array Implantation Surgery and Recordings

Anesthetized Surgery Procedures
On the day of surgery, rats were anesthetized with urethane (25%; 1.25
g/kg).

Once the toe pinch response was absent, rats were secured in a

stereotaxic frame (David Kopf Instruments). The rats were shaved at the surgery
site, and then disinfected using ethanol (70%). A craniotomy was performed,
and stereotaxic coordinates (Paxinos 2009) were used to determine the location
of the mPFC (from bregma, AP: +3.2 mm; ML: ±0.8 mm; DV: -1.5 to -5 mm). A
placement hole for the microelectrode array was drilled into the skull, and in the
contralateral hemisphere, a hole was drilled for reference electrode placement.
The micropipette was loaded with the solution of interest, and connected to a
Picospritzer III (Parker Hannifin, Cleveland, OH).

The microelectrode array

assembly was then stereotaxically placed and lowered to each depth using a
microdrive. The rat brain and surrounding tissues were kept moist during the
experiment using cotton pellets (Richmond Dental, Charlotte, NC).
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Anesthetized Recordings
Once the microelectrode array was lowered to its first depth, the FAST
system software started recording. The recordings were allowed a minimum of
one hour to reach baseline levels before pharmacological manipulations began.
Each time the microelectrode array was lowered to a new depth, a minimum of
ten minutes was given for baseline levels to reestablish.

After baseline was

achieved, multiple ejections of the substance of interest were performed with a
minimum of one minute between each ejection. The rate, pressure, and volume
of the ejections were controlled by the Picospritzer III.

The volume of the

ejections was confirmed using a stereomicroscope that was fitted with a
calibrated reticule.

Awake Freely Moving Surgery Procedures
Prior to surgery, rats were given an injection of carprofen (Rimadyl®,
Pfizer, Inc., New York City, NY; 10 mg/kg, s.c.). Isoflurane (Isothesia, Butler
Schein, Dublin, OH) was used as the anesthetic for all survival surgeries. Initial
anesthesia was induced with 5% isoflurane, and once the rat was secured in the
stereotaxic frame, the isoflurane level was reduced to 2.5%.

Artificial tears

(Rugby Laboratories, Inc., Duluth, GA) were applied to the rat’s eyes. The rat’s
head was shaved, and three applications each of Providone scrub (The Butler
Co., Columbus, OH) and ethanol (70%) were used to disinfect the surgery site.
A craniotomy was performed, and five holes were drilled: one for the
microelectrode array placement, one for the reference electrode placement, and
three for anchoring skull screws. After the skull screws were placed in the skull,
dura was reflected and the microelectrode array was stereotaxically placed in the
IL mPFC (from bregma, AP: +3.2; ML: ±0.8; DV: -4.5 mm), with the reference
electrode positioned in its placement hole. Multiple applications of dental cement
(Ortho Jet Powder and Jet Acrylic Liquid, Lang Dental Manufacturing Co., Inc.,
Wheeling, IL) were used to secure the microelectrode array assembly to the rat’s
skull. The animals were monitored in their home cages following surgery until
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normal locomotion was observed. Animals received daily injections of carprofen
for the three days following surgery.

Awake Freely-Moving Recordings
Recordings began a minimum of 72 hours after surgery. The animal was
hooked up to the connector which consisted of a miniaturized potentiostat
attached to a tether (Figure 2.3), which in turn was hooked up to a swivel in the
recording chamber to allow the animal to move freely within the chamber. Within
the recording chamber, a Digiscan Animal Monitoring device (Omnitech, Inc.,
Sioux Falls, SD) measured animal movement during the experiments. After hook
up, rats were allowed at least one hour to baseline before data was collected.
Rats were monitored during experiments to ensure that they did not interfere with
their tethers. After the experiment, rats were returned to their home cages.

Data Collection
During each experiment, parameters including resting levels of glutamate,
peak amplitude of the glutamate signal (either evoked or spontaneous), T80 (time
for 80% of the signal to decay back to baseline), and uptake rate were collected
and analyzed (Figure 2.4) using a custom Matlab®-based (The Mathworks, Inc.,
Natick, MAJ) analysis package.

Statistics were performed using GraphPad

Prism® 5 (GraphPad Software, La Jolla, CA).

Histology
At the end of an experiment, the animal was euthanized under heavy
anesthesia. The brain was removed and flash frozen with dry ice. Brains were
stored at -80˚C until sliced on a cryostat into 40 µm coronal sections. After being
mounted on slides, brains were stained with cresyl violet and microelectrode
placement in the mPFC was visually confirmed. If the placement could not be
confirmed, the animal was excluded from the study.
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Portions of these methods have been previously published in the manuscript:
Mattinson, C.E., Burmeister, J.J., Quintero, J., Pomerleau, F., Huettl, P.,
Gerhardt, G.A. 2011. Tonic and phasic release of glutamate and
acetylcholine neurotransmission in sub-regions of the rat prefrontal cortex
using enzyme based microelectrode arrays. J Neurosci Methods. 202 (2):
199-208.
Permission was obtained from Elsevier for use.
Copyright © Catherine Elizabeth Mattinson 2012
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Chapter Two: Figures

Figure 2.1 Microelectrode Array Glutamate Coating Schematic
The ceramic tip of the S-2 configuration of the microelectrode array features four
platinum recording sites arranged in two pairs (center). On the bottom pair of
sites, a glutamate oxidase (GluOx) coating is applied (left). When glutamate
(Glu) comes into contact with the glutamate oxidase, it is oxidized into H2O2 and
α-ketoglutarate. The H2O2 is free to diffuse, and when it comes into contact with
a platinum recording site (Pt) while a potential of 0.7 V vs. Ag/AgCl reference is
applied, the H2O2 is oxidized and donates 2 electrons to the site. An exclusion
layer of meta-phenylenediamine (mPD) is electroplated onto the microelectrode
array surface, and serves to insulate the sites from potentially electroactive
substances such as DOPAC and ascorbic acid (AA). The top pair of sites (right)
is coated with the coating matrix lacking enzyme. Thus, it cannot generate a
glutamate signal. The signal from the top pair of sites is subtracted from the
bottom pair of sites to isolate a self-referenced glutamate signal.
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Figure 2.2 In Vitro Calibration of a Glutamate Selective Microelectrode Array
An in vitro calibration is performed before all experiments. Channels 1 and 2 are
coated with glutamate oxidase, and channels 3 and 4 are only coated with the
coating matrix. Phosphate buffered saline (PBS, 0.05M, 40 mL) is heated to
37˚C in a water bath. A microelectrode array and a reference electrode are both
submerged in the PBS, and the recording software is started. After baseline has
been established, 250 µM ascorbic acid (AA; final beaker concentration) is added
to ensure that the exclusion layer is intact.

Next, three serial additions of

glutamate (Glu) are pipetted into the beaker, totaling a concentration of 60 µM.
These stepwise increases in glutamate are used to calculate the slope of the
electrode. An addition of dopamine (DA; final beaker concentration of 2 µM) also
serves to ensure that the exclusion layer is working. Finally, an addition of H2O2
(final beaker concentration of 8.8 µM) is made as a positive control, to ensure
that all recording sites can measure the reporter molecule.
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The recorrding













 

Figure 2.4 Data Parameters of Interest
During the experiment, resting levels of glutamate are calculated by subtracting
the signal from the sentinel sites from the signal from the glutamate recording
sites. Peak amplitude is the peak magnitude of the signal, either from an evoked
release (75-100 nL of KCl (70 mM, pH 7.4); indicated by black arrow) or from a
spontaneous release. The T80 value is the time it takes for 80% of the signal to
decay back to baseline. The uptake rate is the product of the peak amplitude
and the k-1 value. The k-1 value represents the best fit line of the first order decay
of the signal.
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Chapter Three: Tonic and Phasic Release of Glutamate and
Acetylcholine in the Rat Prefrontal Cortex Sub-Regions using
Enzyme-Based Microelectrode Arrays

Introduction
The mPFC is an area of the brain that is critically involved in higher
cognitive processes such as learning, memory, and attention, and within the
mPFC exist multiple sub-regions, including the cingulate, prelimbic, and
infralimbic mPFC. Glutamate and ACh in combination with monoamine
neurotransmitters (Berger et al., 1976; Brown et al., 1979; de Brabander et al.,
1993; Gratton et al., 1989; Perry et al., 2011; Thierry et al., 1983) are essential
for prefrontal cortical functioning.

The mPFC receives glutamatergic inputs from

the thalamus (Gigg et al., 1992; Leonard, 1969; Pirot et al., 1994), basal
forebrain (Henny and Jones, 2008), hippocampus (Gigg et al., 1994; Jay et al.,
1992), and amygdala (McDonald, 1996). This brain area also receives ACh input
from the basal forebrain as part of the basal forebrain cortical cholinergic system
(Mesulam et al., 1983). The loss or antagonism of these specific glutamatergic
and acetylcholinergic afferents has been shown to result in deficits in spatial
working memory (Bailey and Mair, 2005; Romanides et al., 1999), passive
avoidance tasks (Torres et al., 1994), and attention (McGaughy et al., 1996),
highlighting the importance of these neurotransmitter systems in daily cognitive
functioning. Dysregulation of the glutamatergic and/or acetylcholinergic circuitry
in the mPFC has been implicated in disorders such as schizophrenia (Bauer et
al., 2008; Benes et al., 1992; Crook et al., 2001; Olbrich et al., 2008; Oni-Orisan
et al., 2008; Sarter et al., 2005; Tsai et al., 1995; Woo et al., 2008; Zmarowski et
al., 2009), Alzheimer’s disease (Burbaeva et al., 2005; Francis et al., 1999;
Kashani et al., 2008; Perry et al., 2011; Trabace et al., 2007), and drug addiction
(Arnold et al., 2003; Lu et al., 1999; McFarland et al., 2003; Sofuoglu and
Mooney, 2009; Williams and Steketee, 2004).

The overlap and possible

interactions of these two neurotransmitter systems underscores the importance
of understanding both the tonic and phasic aspects of glutamate and ACh
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neurochemical signaling in the mPFC and could lead to a better understanding of
alterations associated with neuropathologies.
In this chapter, we report experiments that used our MEA technology to
gain insight into potential sub-regional differences in tonic and phasic release of
glutamate and ACh in the rat mPFC. We first measured resting neurotransmitter
levels within the cingulate, prelimbic, and infralimbic mPFC. Secondly, we
examined the dynamics of KCl-evoked release of glutamate and ACh in the
cingulate, prelimbic and infralimbic to investigate additional transient or phasic
release of these neurotransmitters. These experiments provide new information
regarding the regional signaling properties of glutamate and ACh in different subregions of the mPFC, an area of the brain that is implicated in many
neuropathologies.

Materials and Methods

Animals
Male Fischer 344 rats (Harlan, Indianapolis, IN), aged 3 – 6 months, were
used for all experiments (n = 17). For care, see Animals.

Microelectrode Array Preparation
Ceramic based conformal MEAs were made sensitive to and selective for
glutamate or ACh detection using enzyme layers coated onto the surface of
platinum (Pt) recording sites (Day, Pomerleau et al. 2006; Burmeister, Pomerleau
et al. 2008). Glutamate coatings are detailed Microelectrode Configuration and
Preparation – Microelectrode Coatings.

MEAs configured for ACh detection

(Figure 3.1) required a dual enzyme coating scheme to produce the H2O2
reporter molecule, as ACh is also non-electroactive. Acetylcholinesterase was
used to hydrolyze ACh into acetate and choline, and then choline was
catalytically oxidized by choline oxidase to produce H2O2 (Bruno et al., 2006).
MEAs were coated with a solution of 0.2 units/µl choline oxidase, 0.9% BSA and
32

0.11% glutaraldehyde on all four sites and allowed to cure at 4˚C for a minimum
of 48 hours.

MEAs were then coated with 0.83 units/µl human recombinant

acetylcholinesterase, 0.83% BSA, and 0.10% glutaraldehyde on one pair of sites,
and the BSA/glutaraldehyde solution on the other pair of sites to ensure
comparable coating thickness between the pairs of sites and to allow for selfreferencing (Burmeister et al., 2008).

In order to enhance selectivity a size

exclusion layer of mPD was electrodeposited on to the Pt recording sites prior to
calibration.

Each of the MEA sites were tested to determine selectivity vs.

dopamine during an in vitro calibration to ensure that the mPD electrodeposited
onto sites was uniform. The signal from the choline oxidase-coated sites was
subtracted from the combined acetylcholinesterase/choline oxidase sites to
determine the self-referenced ACh signal.
All recordings were performed at a final output frequency of 1 Hz. Before
each experiment, MEAs were calibrated in vitro using stepwise additions to
increase concentrations of glutamate or ACh, as well as, electroactive
interferents as previously described (Burmeister and Gerhardt, 2001; Burmeister
et al., 2002).

Sensitivity, linearity, limit of detection, and selectivity over

electroactive interferents were calculated for all MEAs using the in vitro
calibration data prior to experimentation. MEAs used in glutamate experiments
had an average slope of -4.2 ± 2.0 pA/µM, an average limit of detection of 0.99 ±
0.9 µM, a linearity R2> 0.99, and an average selectivity of 57:1 ± 37. In ACh
experiments, MEAs averaged a slope of -5.8 ± 2.6 pA/µM, a limit of detection of
0.30 ± 0.44 µM, a linearity R2> 0.99, and a selectivity of 420:1 ± 720.

In Vivo Recordings
Animals were anesthetized for in vivo recordings, and surgery was
performed (Microelectrode Array Implantation Surgery and Recordings –
Anesthetized Surgery Procedures; Anesthetized Recordings). The micropipette
attached to the MEA was filled with an isotonic KCl solution (70 mM KCl, 79 mM
NaCl, 2.5 mM CaCl2 • 2H2O; pH = 7.4) and connected to a Picospritzer III (Parker
Hannifin Corp, NJ) to allow for local applications of KCl into the extracellular
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space . The MEA/micropipette assembly was lowered into the mPFC (AP: +3.2
mm; ML: ±0.8 mm; DV: -1.5 to -5 mm; from bregma (Paxinos and Watson, 2009)
using a Narishige MO-10 microdrive. The MEA assembly was lowered in 0.5 mm
increments and recordings were taken at each depth to record glutamate or ACh
levels along the dorsal-ventral axis of the mPFC. Once lowered into place, basal
levels were established over ten minute recording durations, and then KCl
solution was ejected (75-100 nl) to evoke glutamate or ACh signals

Histology
At the end of the experiment, animals were euthanized and histology was
performed to confirm MEA placement (Histology; Figure 3.3). Only data collected
from confirmed electrode placements in the different sub-regions of the mPFC
were included in the final data analysis; data from two animals were excluded in
these studies.

Data Analysis and Statistics
Collected data were processed using a custom Matlab®-based analysis
package (Data Collection).

Data parameters analyzed were resting (tonic

release) neurotransmitter levels (average of the ten data points prior to the first
ejection at each depth) and data from KCl-evoked release (phasic release) of
glutamate or ACh that included: peak amplitude, T80 (time for 80% of the signal to
decay to baseline), and k-1, best fit line of first order rate constant of the signal
return to baseline. Glutamate and ACh KCl-evoked peaks were volume matched
(75-100 nL) for data analysis.

Outliers were eliminated from data using a

Grubb’s test before analyses were conducted. As data was not always attainable
at every depth throughout the depth profile due to clogging of the tips of the
micropipettes, occasional data drop out occurred. Thus, a one-way ANOVA with
a Bonferroni post hoc test was used to analyze the KCl-evoked data and resting
levels between glutamate and ACh were analyzed using a two-way ANOVA.
Correlations were also performed to compare the log of KCl-evoked data and
resting data for each neurotransmitter. Significance was defined as p < 0.05.
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Results
Glutamate and Acetylcholine Resting Levels Are Stable Across
Sub-Regions
Glutamate and ACh recordings in the mPFC focused on three subregions: the cingulate, prelimbic, and infralimbic.

For both neurotransmitters,

resting levels were calculated using the self-referenced signals. When average
resting levels of glutamate were compared among brain regions (Figure 3.3),
they were found to be similar (F(2,18) = 0.069; p = 0.93), with only a 0.70 µM
difference between the highest and lowest levels. Interestingly, analyses of
average ACh resting levels revealed comparable resting levels (Figure 3.3;
F(2,17) = 0.47; p = 0.63) of 0.60 – 1.0 µM for the cingulate, prelimbic and
infralimbic mPFC. There was a significant main effect between the two
neurotransmitters (F(1,35) = 16; p = 0.0003), however, the resting levels of
glutamate and ACh were not significantly different within sub-regions of the
mPFC.

KCl-Evoked Glutamate Release is Similar Among Sub-Regions in the
Medial Prefrontal Cortex
KCl-evoked release of glutamate was successfully carried out in the
cingulate, prelimbic and infralimbic sub-regions of the mPFC. Local application of
KCl was seen to produce detectable and transient increases in extracellular
glutamate that lasted for, on average, 3-5 seconds. Representative tracings of
KCl-induced glutamate release from each brain region were compared (Figure
3.4) to illustrate the similar peak amplitudes among the sub-regions of the mPFC.
The tracings indicate the uniformity among signals, with similar peak rise times,
peak amplitudes, and similar decay profiles.
The glutamate peak amplitudes, T80 values, and k-1 values were used to
characterize KCl-evoked release of glutamate. Measures of glutamate release
revealed no significant differences in the peak amplitudes of glutamate (Figure
3.4; F(2,15) = 1.8; p = 0.21) or T80 values (Table I; F(2,16) = 1.9; p = 0.18) in the
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different sub-regions. Glutamate k-1 values were also comparable among brain
regions (Table 3.1; k-1: F(2,16) = 0.31; p = 0.74). Correlations of the log of KClevoked release of glutamate with resting levels of glutamate were not significant
for any sub-region of the mPFC (Figure 3.8; cingulate, p = 0.97; prelimbic, p =
0.12; infralimbic, p = 0.20).

Acetylcholine Signaling Parameters are Similar Among Brain
Regions
Studies were carried out to investigate KCl-evoked release of ACh in the
sub-regions of the mPFC. Similar to the glutamate studies, KCl was seen to
produce detectable and transient release of ACh lasting 5-10 seconds in the
mPFC. The similarity among ACh release and uptake from each brain sub-region
are further illustrated in Figure 3.5.

KCl-evoked ACh peaks rose to peak

amplitudes in a similar manner, and decayed at similar rates, resulting in
comparable signaling parameters among the cingulate, prelimbic, and infralimbic
mPFC. When ACh signaling parameters were compared among the three brain
sub-regions, no significant differences were found suggesting homogeneity of
ACh neurotransmission in the mPFC.

Peak amplitudes showed uniformity,

(Figure 3.5; F(2,26) = 1.1; p = 0.35) thus further characterizing KCl-induced ACh
release among the brain sub-regions. When the log of KCl-evoked releases of
ACh were correlated with ACh resting levels within each sub-region, a significant
difference in the cingulate was found (Figure 3.7; Cg1, p = 0.049).

No

significance was found in either the prelimbic (Figure 3.7; p = 0.93) or the
infralimbic (Figure 3.7; p = 0.29). ACh uptake parameters including T80 values
were also homogeneous (Table 3.2; F(2,23) = 0.32; p = 0.73), as were k-1 values
(Table 3.2; k-1: F(2,26) = 0.096; p = 0.91).

Comparisons of KCl-Evoked Glutamate and Acetylcholine Reveal
Significant Differences Between the Neurotransmitters
We compared the peak amplitudes of both neurotransmitters to contrast
mPFC glutamate and ACh KCl-evoked release (Figure 3.6). While significant
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differences were not found within each neurotransmitter, significant differences
did exist between neurotransmitters. ACh peak amplitude measurements ranged
from 5.3 – 7.1 µM, and glutamate peak amplitude concentrations measured 1.8 –
2.9 µM. Analyses revealed that the peak levels of ACh in the cingulate were
significantly higher than glutamate signals in all sub-regions (F(5,41) = 5.4; p =
0.0007). As compared to glutamate levels in the cingulate sub-region, cingulate
ACh levels were greater by 144%. KCl-evoked ACh release in the cingulate was
also greater by 255% and 294% compared to glutamate levels in the prelimbic
and infralimbic, respectively.
We also compared T80 values between the two neurotransmitters, and
found significant differences in decay times between glutamate and ACh (F(5,39)
= 11; p < 0.0001). In the cingulate mPFC, ACh decay times were increased
200% as compared to glutamate decay times in the same brain sub-region
(Figure 3.6). ACh T80 values in the prelimbic and infralimbic were increased
190% and 330% as compared to glutamate values, respectively.

Discussion
These are the first studies comparing both tonic and phasic release of
glutamate and ACh levels on a second-by-second time scale in individual subregions of the anesthetized rat mPFC. The results of our studies demonstrate
that we can reliably measure both tonic and phasic glutamate and ACh release in
vivo using the MEA technology. The spatial resolution of our MEAs allowed for
the measurement of these neurotransmitters in discrete mPFC sub-regions such
as the cingulate, prelimbic, and infralimbic, and the sampling rate offered the
ability

to

measure

individual

KCl-induced

glutamate

and

ACh

peaks.

Interestingly, our data support that the glutamate and ACh neurotransmitters
systems have tonic and phasic release that are uniform within the sub-regions,
but there were significant differences in both resting and KCl-evoked release of
glutamate vs. ACh in the mPFC.
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Resting Levels of Glutamate and Acetylcholine
These studies did not find significant differences in resting glutamate
levels within the cingulate, prelimbic, and infralimbic mPFC, although there was
marked variability within each mPFC sub-region. We had initially hypothesized
that we would see differences among the sub-regions for glutamate resting
levels, as glutamate is tightly regulated in the mPFC (Hascup et al., 2010). Thus,
the relative homogeneity of our glutamate resting levels within the mPFC subregions was unexpected, but not unprecedented. Previous MEA work within our
lab has shown that glutamate resting levels in anesthetized animals do not differ
greatly between brain regions. We have reported resting glutamate levels in
anesthetized rats of 1.6 ± 0.30 µM in the frontal cortex and 1.4 ± 0.20 µM in the
striatum, and in the hippocampus, we have measured glutamate concentrations
ranging from 2.5 µM in the CA1 region to 3.4 μM in the dentate gyrus (Stephens
et al., 2009). Our glutamate resting levels of 3.7 - 4.3 µM in mPFC sub-regions
are higher than previously reported levels from MEA studies in other brain
regions, but not unreasonable.

Resting levels of glutamate that have been

measured using microdialysis in the mPFC have ranged from 0.23 ± 0.061 µM to
3.8 ± 0.40 µM (Del Arco et al., 1998; Ferraro et al., 2001; Hugues et al., 2007;
Karreman and Moghaddam, 1996; Lupinsky et al., 2010) and 3.0 ± 0.60 µM in
the striatum (Miele et al., 1996). Compared with microdialysis measures, our
resting levels of glutamate are over 600% higher than previously reported
microdialysis glutamate levels in the mPFC of the same strain (Selim and
Bradberry, 1996).

However, this difference in concentration between MEA

technology and microdialysis measures can be explained because the MEAs
sample the extracellular space of the brain directly rather than being separated
by a membrane containing a net analyte concentration of zero driving diffusion
into the microdialysis probe. Also, far less edema or gliosis occurs with MEAs
than microdialysis probes, allowing for better estimates of neuronally-based
release vs. release from other sources.
The Pt recording sites on the MEA only measure neurotransmitters that
come into contact with the surface of the electrode (Burmeister et al., 2000). We
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have hypothesized that our increased glutamate resting levels and higher ACh
resting levels may be the result of the enhanced spatial resolution of our MEAs
that allows us to be closer to synaptic spillover, as evidenced by studies using
tetrodotoxin (Day et al., 2006). Microdialysis probes may be able to pick up
some spillover, but the size of the probe membranes and the inherent time
constant of the microdialysis membrane (Schultz and Kennedy, 2008) are
prohibitive for measuring neurochemical activity at the level of synapses
(Timmerman and Westerink, 1997). Thus, the MEAs measure the concentration
of the neurotransmitter that resides in the extracellular space and do not record a
fractional level. Our recently reported studies support that this translated to a 510 fold difference of resting levels of glutamate measured by MEAs versus
microdialysis in the awake animal and is largely due to the direct measurement
of the neurotransmitter concentration in the extracellular space by the MEA
technology (see Hascup et al., 2010).
In our first paper using MEA technology to measure ACh (Bruno et al.,
2006), we did not report resting levels. However, in this set of studies we are
now able to report for the first time in vivo resting levels of ACh using MEA
technology. Similar to our glutamate hypothesis, we predicted that we would see
significant differences in ACh resting levels among the sub-regions of the mPFC.
We did not find any significant differences in resting levels of ACh among the
mPFC sub-regions, and little variability existed within each sub-region. Reported
resting levels of ACh in the mPFC have widely varied from 0.58 ± 0.14 nM to 3.0
± 0.3 µM in microdialysis studies (Arnold et al., 2001; Hernandez et al., 2008;
Huang et al., 2008; Mork et al., 2009; Neigh-McCandless et al., 2002). Our ACh
measurements of 0.59 – 0.96 µM fall into the higher end of the range of these
previously reported microdialysis ACh concentrations. Microdialysis, with its
collection times on the scale of several seconds to minutes, may allow for more
ACh

hydrolysis

by

acetylcholinesterase,

resulting

in

lower

reported

concentrations. Thus, many scientists who use microdialysis for measuring ACh
levels also perfuse an acetylcholinesterase inhibitor, such as neostigmine, to
prevent ACh breakdown (Nirogi et al., 2010; Ragozzino et al., 1996). However,
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this technique may artificially affect the measured ACh levels in the extracellular
space. The detection of higher levels of both glutamate and ACh can be
attributed to the improved spatial and temporal resolution of the MEA.
The present series of studies was carried out in anesthetized animals to
take advantage of the brain mapping capability of the MEAs to record glutamate
and ACh levels in different sub-regions of the mPFC in the same rat. Work from
our group has shown that the administration of urethane anesthesia to awake,
freely moving rats resulted in a 58% decrease in resting glutamate levels
(Rutherford et al., 2007). Thus, it is likely that the anesthetic attenuated
glutamate resting levels in these studies and possibly affected ACh levels as
well. Even with this possible attenuation, our glutamate resting levels are still
relatively high compared to microdialysis studies, but this likely relates to the
aforementioned properties of the MEA measurements as compared to
microdialysis. By contrast, to date we do not have any indication that urethane
affects KCl-evoked release of glutamate based on our work (data not shown).
Urethane has also been shown to enhance the actions of the nicotinic ACh
receptor, but only to a small degree (Hara and Harris, 2002). Future studies will
be carried out in the awake animal to circumvent the potential effects of
anesthesia. It should also be noted that glutamate and ACh levels in the mPFC
vary with rat strain. For example, glutamate levels in awake rats have been
reported from 0.22 µM in Sprague-Dawley rats (Ferraro et al., 2001) to 4.2 µM in
Wistar-King rats (Abekawa et al., 2000).

ACh levels in rats exhibit an even

greater range of resting levels, from 0.58 nM in awake Sprague-Dawley rats
(Huang et al., 2008) to 3.0 µM, also in awake Sprague-Dawley rats (Mork et al.,
2009). Thus, the concentrations reported in the present studies were likely
affected by anesthesia and were likely dependent on the strain used.
A comparison of our resting levels of glutamate and ACh in mPFC subregions did not reveal any differences within neurotransmitters, but we did see a
significant

main

effect

between

neurotransmitters,

suggesting

that

the

neurotransmitter resting levels do vary between glutamate and ACh within the
mPFC. This may be due to the differential innervation of the mPFC by theses
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neuronal systems and/or the regulation of these neurons by other neurons and
signaling molecules.

Interestingly, our resting levels of ACh were extremely

similar between the prelimbic and infralimbic sub-regions, suggesting that ACh
regulation is uniform in these areas.

This is supported by microdialysis

experiments that have sought to characterize sub-regions of the mPFC, and
have reported similar resting levels between the prelimbic and infralimbic mPFC
(Hedou et al., 2000).

However, it should be noted that there was overlap

between sub-regions due to the spatial resolution of the microdialysis technique.

Measurements of KCl-Evoked Release of Glutamate and
Acetylcholine in the Rat Medial Prefrontal Cortex
Although no significant differences were found in KCl-evoked glutamate
release, both the peak amplitudes and the T80 values followed trends along the
dorsal-ventral axis in the mPFC (Table 3.1).

In previous microdialysis studies

that used KCl to evoke neurotransmitter release, the infusion of KCl into the
mPFC resulted in an increase in glutamate levels of 90% (Frantz et al., 2002).
KCl has also been reported to have no effect on glutamate levels (Welty and
Shoblock, 2009). However, these studies were not specific to sub-regions of the
mPFC, and they did not measure rapid changes in glutamate or ACh. We saw
that glutamate peak amplitudes decreased approximately 38% from the cingulate
to the infralimbic mPFC, while T80 values in the infralimbic mPFC were also
decreased by 44% as compared to T80 values in the cingulate sub-region. These
findings are suggestive of subtle variance in the amounts of glutamate released
in response to KCl, and in the time needed for 80% signal decay among mPFC
brain sub-regions that also could relate to the extent of glutamate regulation by
glutamate transporters located primarily on glia in sub-regions of the mPFC
(Danbolt, 2001). Additional studies are needed to further investigate this finding.
Our studies showed that potassium stimulation was seen to produce
increases in extracellular ACh that ranged from roughly 500-1000% of the
baseline or tonic ACh levels. A previous microdialysis study showed that
potassium stimulation produced an increase in ACh levels of 650% (Herzog et
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al., 2003). Thus, the relative change from baseline or tonic ACh levels seen from
potassium stimulation was in the range of that reported by microdialysis.
Interestingly, our KCl-evoked ACh peak amplitude values followed a pattern
similar to that of glutamate along the dorsal-ventral axis of the mPFC. Both ACh
peak amplitudes and ACh uptake rates were decreased in more ventral areas as
compared to dorsal areas. Our T80 values in the infralimbic sub-region were
found to be consistent with a previous study using our ceramic based MEAs
(Bruno et al., 2006).
When we compared our glutamate and ACh peak amplitudes, we found
that the ACh peak amplitude concentrations were significantly higher in the
cingulate region of the mPFC (7.1 µM) than the glutamate concentrations in all
sub-regions (1.8-2.9 µM).

Acetylcholinesterase distribution in the mPFC is

known to be heterogeneous (Mrzljak and Goldman-Rakic, 1992; Rajkowska et
al., 1993). Thus, the varying amounts of this enzyme may be responsible for the
significant ACh concentration differences. It has also been shown that the basal
forebrain projects directly to the cingulate, among other areas of the mPFC (Bigl
et al., 1982; Houser et al., 1985), and this may account for increased release of
ACh. Additionally, the tight regulation of the glutamate signaling (Hascup et al.,
2010) may result in decreased amounts of glutamate release. Our higher
observed glutamate resting levels may be sufficient to maintain glutamatergic
tone within the mPFC. Our studies also found significant differences in T80 values
between glutamate and ACh within all sub-regions.

ACh T80 values in the

cingulate, prelimbic, and infralimbic mPFC were all significantly increased as
compared to glutamate T80 values in the same brain sub-regions (Figure 3.6).
These increased decay times seen in KCl-evoked release of ACh suggest that
glutamate is being cleared more rapidly than ACh.

This may be due to the

separate processes that govern the breakdown of these neurotransmitters.
Glutamate clearance from the extracellular space is dictated by a number of
factors, including diffusion and the presence of high affinity glutamate
transporters (Danbolt, 2001).

Extracellular ACh is rapidly broken down by

endogenous acetylcholinesterase. In addition to diffusion, choline is removed
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from the extracellular space via sodium dependent high affinity choline
transporters (Okuda et al., 2000) and through low affinity transport (Meyer et al.,
1982). Our data suggests that, based on our T80 values, glutamate transport
may be occurring on a faster time scale than the hydrolysis of ACh and transport
of choline.
For these ACh experiments, we used a human recombinant source of
acetylcholinesterase in our coating solution. Many studies (Bruno et al., 2006;
Giuliano et al., 2008) used acetylcholinesterase from an eel source, which
became unavailable from vendors for a period of time in 2006. When the eel
source of acetylcholinesterase was reintroduced, we observed that it had
markedly lower unit activity than before (≥1000 units/mg of protein), thus limiting
the ability of the MEAs to measure ACh. An SDS-PAGE gel analysis of the eel
source of AChE revealed the presence of possible impurities and/or degradation
products, in addition to the AChE protein (Figure 3.9; Dr. Luke Bradley,
unpublished work). This less reliable form of the enzyme was used for a number
of experiments, with fairly poor results. Thus, we were forced to look for an
alternative source of acetylcholinesterase. The human recombinant version of
this enzyme proved to be a viable option for coating, with its higher unit activity
(≥2000 units/mg of protein).

We feel that the human recombinant

acetylcholinesterase corrected the previous problems of measuring ACh
associated with the eel source of acetylcholinesterase. The human recombinant
acetylcholinesterase, as well as our curing protocol, has allowed us to optimize
MEAs for in vivo ACh detection (Burmeister et al., 2008) and to carry out the
studies described in this study.
The cholinergic system is a complex network that uses and ACh for
neurochemical signaling. It has been postulated that the in vivo hydrolysis of
ACh by acetylcholinesterase occurs so rapidly (Lawler, 1961) that little ACh can
escape the synaptic cleft intact, and thus measuring choline is a suitable
alternative (Giuliano et al., 2008). Our data presented in this paper contradicts
this hypothesis, as evidenced by our prelimbic resting ACh concentrations of 1.0
± 0.7 µM, which are at least one order of magnitude higher than the levels of
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0.058 – 120 nM (Brooks et al., 2007; Del Arco et al., 2007; Huang et al., 2008;
Prus et al., 2007) reported in recent microdialysis studies performed in the mPFC
of awake rats. The amplitudes of ACh measured from the KCl-evoked measures
in this study yielded peak amplitude concentrations of 7.1 ± 3.9 µM, which were
similar to those previously reported using MEA technology (Bruno et al., 2006).
Even more impressive, these calculations are based on a self-referenced signal
that subtracts the background current produced by the breakdown of choline.
Thus, we can conclude that the subtracted signal likely reflects ACh
concentrations in the mPFC, and that these ACh levels are robust enough to
warrant investigations separate from those of choline when they are measured
on a second-by-second time scale.
Finally, we sought to examine the relationships between resting levels of
neurotransmitters and the KCl-evoked release of neurotransmitters. Over the
course of analyzing our data, we noticed increased resting levels of glutamate
with decreased KCl-evoked release of glutamate compared to ACh. The two
neurotransmitters almost seemed to have an inverse relationship to each other in
these two parameters. We were interested in whether the KCl-evoked release of
a neurotransmitter was correlated to its resting levels, so we performed
correlations for each neurotransmitter within the three sub-regions (Figure 3.7).
The correlation between the log of the evoked release of ACh and resting levels
of ACh in the cingulate was found to be significant.

We did not see any

significant correlations in our glutamate data, nor did we find significance in the
prelimbic and infralimbic sub-regions for ACh. These findings suggest that the
tonic and phasic aspects of signaling in the mPFC are independent of each
other.

However, resting ACh levels may be predictive of KCl-evoked ACh

release in the cingulate mPFC.

Conclusions
In conclusion, we believe that this series of studies is critical to furthering
our understanding of prefrontal cortex neurochemistry.

We observed no

significant differences in tonic and phasic release of glutamate or ACh in sub44

regions of the mPFC. However, we did see greater amounts of resting glutamate
compared to resting ACh levels in the three sub-regions of the mPFC. In
addition, the amount of KCl-evoked ACh release was greater as compared to
KCl-evoked glutamate release in all sub-regions of the mPFC. Finally, when the
KCl-evoked signals of glutamate or ACh were expressed relative to baseline, it
was found that KCl-evoked ACh release was 500-1000 % of baseline whereas
glutamate was no greater than 100% of baseline, supporting that there was
evidence for potential autoregulation of both neurotransmitters. The next step is
to continue these recordings in awake, freely moving animals with the goal of
exploring glutamate and ACh signaling in the prefrontal cortex during behavior
without the potential confound of anesthesia. Also planned are experiments that
use drugs such as TTX and TBOA to determine the neuronal contribution to
glutamate and ACh signals in the mPFC. Additionally, while these studies used
separate MEAs to measure glutamate and ACh, the development of a novel MEA
design that allows for measurement of multiple chemicals of interest at the same
time (Hascup et al., 2007) should prove to be very useful for determining
relationships between different neurotransmitter systems in vivo.

Portions of this chapter have been previously published in the manuscript:
Mattinson, C.E., Burmeister, J.J., Quintero, J., Pomerleau, F., Huettl, P.,
Gerhardt, G.A. 2011. Tonic and phasic release of glutamate and
acetylcholine neurotransmission in sub-regions of the rat prefrontal cortex
using enzyme based microelectrode arrays. J Neurosci Methods. 202 (2):
199-208.
Permission was obtained from Elsevier for use.
Copyright © Catherine Elizabeth Mattinson 2012
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Chapter Three: Figures

Figure 3.1 Microelectrode Array Acetylcholine Coating Schematic
For the detection of ACh, one pair of sites is coated with human recombinant
acetylcholinesterase (AChE) and choline oxidase (ChOx), while the other is
coated with only ChOx. When ACh comes into contact with the enzyme layers,
AChE hydrolyzes ACh into choline and acetate. The choline is in turn oxidized
by the ChOx into H2O2 and betaine. Similar to the glutamate MEA, the H2O2 is
oxidized at the Pt site producing a signal current that is directly proportional to
the concentration of choline. mPD is used to exclude electroactive interferents
such as AA. The sentinel ChOx coated sites generate a choline signal, which is
subtracted from the combined ACh/choline signal, resulting in a self-referenced
ACh signal for measures of ACh resting levels.
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Figure 3.3 Microelectrode Array Placement in the Medial Prefrontal Cortex
Histological section with cresyl violet staining showing minimal damage produced
by the MEA. Histological sections were used to confirm placement in the mPFC
cingulate (Cg1), prelimbic (PrL), and infralimbic (IL). Adapted from Paxinos and
Watson, 2009.
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Figure 3.4 Resting or Tonic Levels of Glutamate and Acetylcholine in SubRegions of the Medial Prefrontal Cortex
A) Resting levels of glutamate were homogeneous and not significantly different
within sub-regions of the mPFC. (n = 7 for all regions). B) Resting levels of ACh
were not significantly different within sub-regions of the mPFC (Cg1 and IL, n = 6;
PrL, n = 8).

Each color represents a different animal within both

neurotransmitters.
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Figure 3.5 KCl-Evoked Glutamate Release in the Medial Prefrontal Cortex
A) Shown are representative signals from the Cg1, PrL and IL of the mPFC. The
arrow marks the ejection of KCl to evoke phasic release of glutamate. B) Graphs
showing the maximum amplitudes of KCl-evoked release in the different subregions of the mPFC. The average amplitudes of KCl-evoked glutamate release
were not significantly different in the three brain regions. Each color represents a
different animal.
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Figure 3.6 KCl-Evoked Acetylcholine Release in Sub-Regions of the Medial
Prefrontal Cortex
A) Shown are single traces of KCl-evoked ACh release from the Cg1, PrL and IL
of the mPFC. The arrow marks the ejection of KCl to evoke phasic release of
Ach. B) Graphs showing average amplitudes of KCl-evoked ACh release in the 3
sub-regions of the mPFC. There was no significant difference in the ACh
amplitudes within the different sub-regions along the dorsal-ventral axis of the
mPFC. (Cg1 and PrL, n = 10; IL, n = 9). Each color represents a different
animal.
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Figure 3.7 Comparisons of Glutamate and Acetylcholine Peak Amplitudes and
T80 Values in Different Sub-Regions of the Medial Prefrontal Cortex
A) Significant differences were found between the KCl-evoked ACh signal
amplitudes (orange circles) in the Cg1 (**p < 0.01; *p < 0.05; Glu: n = 6; ACh:
Cg1 and PrL, n = 10, IL, n = 9) as compared to glutamate signaling (green
squares) in the three sub-regions of the mPFC. B) T80 values differ significantly
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between glutamate and ACh in each sub-region (***p < 0.001; **p < 0.01; *p <
0.05; Glu: Cg1 and IL, n = 6, PrL, n = 7; ACh: Cg1 and PrL, n = 9, IL, n = 8).
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Figure 3.8 Correlations of Glutamate and Acetylcholine Peak Amplitudes and
Resting Levels
A, B, C) The correlations of the log of KCl-evoked glutamate peak amplitudes
and glutamate resting levels were not significant (Cg1 and PrL, n = 5; IL, n = 5).
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D, E, F) The log of KCl-evoked ACh peak amplitudes and ACh resting levels
showed a significant correlation in the Cg1 sub-region of the mPFC (p < 0.05).
Other sub-regions did not show any significant correlations (Cg1 and IL, n = 6;
PrL, n = 8).
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Table 3.1 KCl-Evoked Glutamate Release Data
Sub-region

Peak

T80 Value

k-1

Amplitude
Cg1

2.9 ± 0.9 µM

3.2 ± 1.8 s

0.7 ± 0.7 s-1

PrL

2.0 ± 1.1 µM

3.0 ± 1.2 s

0.6 ± 0.9 s-1

IL

1.8 ± 1.1 µM

1.8 ± 0.6 s

0.8 ± 0.9 s-1

Peak amplitudes, T80 values, and k-1 values for each of the three sub-regions
highlight the homogeneity of the mPFC (mean ± SD; Cg1 and IL: n = 6; PrL: peak
amplitude, n = 6, T80 value and k-1, n = 7).
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Table 3.2 KCl-Evoked Acetylcholine Release Data
Sub-region

Peak

T80 Value

k-1

Amplitude
Cg1

7.1 ± 3.9 µM

6.3 ± 1.7 s

0.3 ± 0.4 s-1

PrL

5.3 ± 2.4 µM

5.7 ± 1.5 s

0.3 ± 0.3 s-1

IL

5.3 ± 2.7 µM

6.0 ± 1.9 s

0.3 ± 0.3 s-1

Peak amplitudes, T80 values, and k-1 values for each of the three sub-regions
highlight the homogeneity of the mPFC, and ACh release data (mean ± SD; Cg1
and PrL: peak amplitude and k-1, n = 10, T80 value, n = 9; IL: peak amplitude, and
k-1, n = 9, T80, n = 8).
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Chapter Four: Glutamatergic Recordings in the Infralimbic Prefrontal
Cortex of Awake Freely Moving Rats:
Circadian Data and Phasic Glutamate Signaling
Introduction
Microdialysis
neurotransmission.

has

traditionally

been

used

to

measure

in

vivo

However, with collection times in the range of minutes

(Nandi and Lunte 2009), microdialysis is unable to measure phasic changes in
glutamate signaling. MEA technology can sample glutamate concentrations in
vivo on a sub-second time scale (Burmeister, Pomerleau et al. 2002), thus
greatly improving upon the temporal resolution of microdialysis. This advanced
temporal resolution is necessary for the detection of glutamate ‘transients’.
Transients are rapid, dynamic increases in glutamate that have been observed in
multiple brain regions and multiple rat strains using MEAs (Hascup, Hascup et al.
2011).
In addition to the temporal advantages of MEAs, this technology allows for
the measurement of distinct brain sub-regions including the infralimbic mPFC, as
the MEA only measures substances that come into contact with the surface of
the Pt recording sites (Burmeister, Moxon et al. 2000).

Rutherford et al.

demonstrated the ability to modify MEA technology for use in the awake freelymoving animal, thus allowing for simultaneous measurements of glutamate and
behavior (Rutherford, Pomerleau et al. 2007). The advanced spatial resolution of
the MEA and these modifications will allow us to record glutamate signaling from
the infralimbic mPFC on a sub-second time scale without the confound of
anesthetic.
The infralimbic sub-region of the mPFC was investigated in these studies.
The infralimbic mPFC is a ventral portion of the mPFC that has been shown to be
important for working memory (Ragozzino and Kesner 1998; Delatour and
Gisquet-Verrier 1999), attention (Birrell and Brown 2000), goal-directed behavior
(Killcross and Coutureau 2003), impulsivity (Murphy, Dalley et al. 2005), and
extinction (Morgan and LeDoux 1995; Morgan and LeDoux 1999; Peters,
LaLumiere et al. 2008).

Glutamatergic neurotransmission in the infralimbic
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mPFC has not been well characterized in the awake, freely moving animal. The
poor spatial resolution of microdialysis probes has been prohibitive in measuring
specific sub-regions of brain structures. Thus the infralimbic and prelimbic areas
of the mPFC have typically been grouped together as the ventral mPFC (Dalley,
Cardinal et al. 2004), despite the possibility that differential glutamate signaling
may exist between these two regions.
The infralimbic mPFC receives input from the suprachiasmatic nucleus
(SCN) via the paraventricular thalamic nucleus (Sylvester, Krout et al. 2002). As
the SCN serves as the circadian pacemaker of the brain (Kalsbeek, Palm et al.
2006), we extended our awake freely-moving glutamate recordings to 24 hour
time periods to investigate the possibility of circadian influences on glutamate
neurotransmission in the infralimbic mPFC.
We hypothesized that we would be able to detect rapid, dynamic
glutamate transients in the infralimbic mPFC using MEA technology, as well as
measure tonic glutamate levels.

We also hypothesized that we would see

changes in glutamate signaling related to the light and dark cycles during a 24
hour time period.

Materials and Methods

Animals
Male F344 rats, aged 3-6 months were used in these studies (for care,
see Animals). Animals were maintained on a 12 h light: 12 h dark cycle (lights on
at 06:00 h). During the 24 hour recordings, animals had ad libitum access to
water and food in the recording chambers.

Following MEA implant surgery,

animals were monitored and weighed daily. If an animal weighed less than 80%
of its pre-surgery weight, recordings were not performed that day.
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Microelectrode Array Preparation
To optimize the MEA for chronic recordings, the MEA circuit board was
minimized, and the MEA was epoxied to a plug/connector assembly
(Microelectrode Array Configuration and Preparation – Modifications for Awake
Freely-Moving Recordings). MEAs were made selective for glutamate through
the use of glutamate oxidase coating layers (Microelectrode Array Configuration
and Preparation – Microelectrode Array Coatings).

For in vivo chronic

recordings, Nafion® was used as the exclusion layer (Microelectrode Array
Configuration and Preparation – Exclusion Layers) to prevent electroactive
interferents from coming into contact with the Pt recording sites.

Prior to

implantation, MEAs were calibrated in vitro (Microelectrode Array Calibrations).
For awake freely-moving MEAs, the calibrations were performed within the
recording chamber to best simulate the environment in which the recordings
would take place. After calibration, MEA ceramic tips and reference electrodes
were soaked in phosphate buffered saline (PBS; 0.05 M) until the implantation
surgery.

Microelectrode Array Implant Surgery
MEA implant surgery procedures are described in Microelectrode Array
Implant Surgery and Recordings – Awake Freely-Moving Surgery Procedures.
Surgical tools were autoclaved for the first surgery of the day, and sterilized in a
glass bead sterilizer for any subsequent surgeries. Total time for each surgery
was approximately one hour.

Awake Freely-Moving Recordings
All recordings were performed at 4 Hz. Typically, each animal underwent
two 24 hour recording sessions. Recordings were carried out as described in
Microelectrode Array Implant Surgery and Recordings – Awake Freely-Moving
Recordings. Animals were connected and allowed to baseline for approximately
one hour before the 24 hour recording session began. During the recording
session, animals remained in the recording chambers within a sound-isolated
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room. The experimenter occasionally entered the room during the light cycle to
monitor the animal and check to ensure that the tether was not tangled. After the
24 hour recording session, the animal was returned to its home cage for a
minimum of 20 hours before the second 24 hour recording session was carried
out.

Locomotor Activity Monitoring
During the experiments, animals were placed in a Digiscan animal activity
monitoring device inside of the recording chamber.

Multiple parameters of

locomotion, including distance traveled and number of movements, were
measured in five minute time bins over the course of the 24 hour sessions using
Oasis software.

Locomotor activity was measured for the entire duration of

electrochemical recording sessions.

After a recording session, the recording

chamber was cleaned with Roccal disinfectant (Pfizer, Inc., New York City, NY).

Histology
After the experiments, animals euthanized under heavy anesthesia and
their brains were removed to check for MEA placements.

For details, see

Histology. Animals with MEA placements outside of the IL cortex were excluded
from data analysis.

Data Analysis and Statistics
Collected data were processed using a custom Matlab®-based analysis
package (Data Collection). Data parameters of interest included resting levels of
glutamate, glutamate peak amplitudes, T80 values, and uptake rates.

To

examine phasic glutamate activity, recordings were scanned using a peak finder
tool with a threshold set at a minimum of a signal-to-noise ratio of 2.5. A oneway repeated measures ANOVA with a Bonferroni post hoc test was used for
analyses, as were correlation statistics. Significant was defined as p < 0.05.
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Results
24-Hour Signaling Parameters Show Significant Effects
Variable resting levels of glutamate (15 min bins of average glutamate
resting levels were averaged together for the light and dark cycles; average ±
SD: light 10 ± 20 µM, dark 8.7 ± 12 µM) both increase and decrease over a 24hour period, and a significant effect of time was found on glutamate resting levels
(F(4,95) = 220; p < 0.0001; n = 5). Bonferroni post hoc comparisons revealed
significant differences between all animals. 24-hour recordings in the infralimbic
area of the mPFC show the number of transients (Figure 4.1) in a 15 minute
period varying, on average, between 10 and 40 events. Analyses revealed a
significant effect of time on number of glutamate transients (F(4,95) = 37; p <
0.0001; n = 5), and Bonferroni post hoc comparisons showed significant
differences between all animals, except for green and blue, green and black, and
purple and orange

Additionally, the peak amplitude concentration of the

transients showed a significant effect of time on glutamate transient peak
amplitudes (F(3,95) = 180; p < 0.0001; n = 4). Bonferroni post hoc comparisons
revealed significant differences between all animals, except purple and orange.

Significant Correlations Exist Between Glutamate Signaling
Parameters
Negative correlations exist between glutamate concentrations and the
number of glutamate events (Figure 4.2) during both the light (R2 = 0.15; p =
0.0001; n = 4) and dark cycles (R2 = 0.047; p = 0.044; n = 4). Distance traveled
and glutamate concentrations also negatively correlated during the light cycle
(Figure 4.3; R2 = 0.099; p = 0.0010; n = 5), but did not correlate during the dark
cycle. Distance traveled did not correlate with the number of glutamate events
during either portion of the light cycle.

Discussion
This set of experiments sought to further our understanding of tonic and
phasic aspects of glutamate signaling in the infralimbic sub-region of the mPFC
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over the course of a circadian cycle. Our studies confirmed the existence of
rapid, dynamic transient glutamate signaling events in the infralimbic mPFC. We
also observed significant effects over the 24 hour recording period.

Finally,

correlations were revealed between transient events and transient glutamate
peak amplitude concentrations, and between locomotor activity and transient
glutamate peak amplitude concentrations. These findings suggest relationships
among aspects phasic glutamate signaling and locomotion in the infralimbic
mPFC.
Glutamate Resting Levels Vary Among Individual Animals
When glutamate resting levels were analyzed over a 24 hour time period,
we did not find patterns of signaling that indicated a circadian influence on
glutamate neurotransmission. Previous work using microdialysis has resulted in
mixed outcomes. Using polygraphic recordings to determine activity states,
studies have reported no change in glutamate levels in the mPFC (Lena, Parrot
et al. 2005), as well as an increase in glutamate levels during REM sleep in the
orbitofrontal cortex (Lopez-Rodriguez, Medina-Ceja et al. 2007). Another study
using MEA technology to measure glutamate during the sleep cycle showed
increased glutamate levels during waking and REM sleep in the infralimbic
mPFC, and reported resting glutamate concentrations of 15 ± 4.1 µM (Dash,
Douglas et al. 2009). Our reported resting levels of glutamate in the infralimbic
sub-region ranged from approximately 1 µM to 20 µM among five animals, with
averages of 10 µM and 9 µM during the light and dark cycles, respectively. Our
averages differ from those of Dash et al. due to differences in circadian
quantification and strain. We analyzed our data in terms

of the light and dark

cycles of a 24 hour time period, whereas Dash and colleagues used EEG and
EMG to monitor animal activation states. Additionally, our experiments were
performed in F344 rats while their research used Wistar Kyoto rats. Wistar Kyoto
rats originating at Charles River Laboratories have been postulated to be a
model of the inattentive type of ADHD, and unpublished work from our lab has
reported increased resting glutamate levels and evoked glutamate release in the
PFC as compared to control strains.

When we examined individual animals
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(Figure 4.1, D; each color represents a different animal, and the color was
consistent over all figures), we found that two animals showed decreasing
glutamate levels over the 24 time period (purple decreased by 54%, blue
decreased by 33%), one animal showed increasing levels (black increased by
38%), one animal remained relatively constant (orange decrease by 11%), and
one animal had relatively large fluctuations in resting levels of glutamate (green).
These differences underscore the potential for variability among individual
animals, and the MEA’s ability to measure these differences.
We have previously reported glutamate resting levels of 3.7 µM in the
infralimbic mPFC of urethane-anesthetized rats (Mattinson, Burmeister et al.
2011). The 270% increase in our freely-moving resting glutamate levels of 10
µM as compared to anesthetized resting glutamate levels can be accounted for
by the effects of anesthesia. Our laboratory has shown that urethane anesthesia
administration resulted in significantly decreased resting levels of glutamate
(Rutherford, Pomerleau et al. 2007).

Additionally, it should be noted that

anesthetized studies sampled the infralimbic mPFC from two depths, -4.5 and -5
mm, while awake freely-moving studies only sampled from one depth, -4.5 mm.
This difference in the area of the infralimbic mPFC that was sampled for these
experiments may account for some of the differences in glutamate resting levels
between the anesthetized and awake studies as well.

Glutamate Transients and Peak Amplitudes Are Not Influenced By
the Circadian Cycle
Following recording sessions, data were examined for the presence of
transient glutamate signaling events. These phasic changes in glutamate are
characterized by their rapid time course, their intermittent appearance during a
recording, and their signal that is only recorded on MEA sites that are coated for
glutamate detection. It is hypothesized that these glutamate transients are the
result of synaptic spillover. Due to the advanced spatial and temporal resolution
of the MEA, synaptic spillover can be detected to a degree never before
reported. Hascup and colleagues were the first to report these dynamic changes
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in glutamate neurotransmission as measured by MEA technology (Hascup,
Hascup et al. 2011), but another group using biosensors has also recently
reported the presence of these transients in the amygdala (Wassum, Tolosa et
al. 2012).

This group also reported an increase in the number of transients

during a lever pressing task, and concluded that glutamate transients may be
important for decision making processes. The experiments in this chapter sought
to measure glutamate transients over the course of a 24 hour time period. Our
data did not reveal any significant patterns in transient glutamate signaling
corresponding to the circadian cycle.

However, our studies provide further

support for the existence of this dynamic phenomenon (see inset of Figure 4.4).
Peak amplitude concentrations of glutamate transients were also
quantified over the circadian cycle. Once again, patterns associated with the
light and cycle did not emerge during analysis.

Our peak amplitude

concentrations averaged 1.9 µM for the light cycle, as well as 1.9 µM for the dark
cycle, thus indicating a uniformity of glutamate transient peak amplitudes over
the course of 24 hours. Interestingly, these concentrations are similar to the KClevoked 1.8 µM average peak amplitude concentration we reported in a previous
study in the infralimbic mPFC (Mattinson, Burmeister et al. 2011). This indicates
that glutamate release in the infralimbic sub-region is not affected by urethane
anesthesia, as the concentrations are consistent between anesthetized and
awake freely-moving experiments. Additionally, the similar peak amplitudes of
KCl-evoked release and glutamate transients suggest a similar regulation.

Correlations Exist Between Glutamate Signaling Parameters and
Locomotion
To

further

examine

relationships

between

glutamate

signaling

parameters, we performed a series of correlations on our data for both the light
and dark portions of the circadian cycle.

When the number of glutamate

transients was compared to the peak amplitudes of those transient events, we
found significant negative correlations in both the light and dark cycles.
Glutamate transients have been shown to be TTX dependent, thus suggesting
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vesicular glutamate release (Wassum, Tolosa et al. 2012).

As glutamate

transients increased in frequency in our experiments, transient peak amplitude
concentrations decreased, most likely due to the decreased time available to
repackage glutamate before the next transient event. This finding is consistent
with the tight regulation associated with in vivo glutamate signaling (Danbolt
2001).
Locomotor activity, defined as distance traveled, was also compared to
glutamate transient peak amplitudes, and a significant negative correlation was
only found during the light cycle. Thus, we observed a decrease in transient
peak amplitude associated with increased movement. This relationship was not
observed during the dark cycle.

From examining the data, we can see that

overall movement was increased during the dark cycle, as expected with a
nocturnal species such as rats, but transient glutamate concentrations remained
relatively consistent. Locomotor activity was also compared to the number of
glutamate transients during the dark cycle, and no significant relationships were
found (data not shown).

These findings indicate that locomotor activity

associated with dark portion of the circadian cycle is independent from transient
glutamate signaling.

As transient increases in glutamate are only recently

reported, and only one other study has used MEAs to measure glutamate over a
24 hour time period (Dash, Douglas et al. 2009), it is difficult to compare our
findings to existing literature.

Conclusion
These experiments have not only confirmed the presence of transient
glutamate signaling in the infralimbic mPFC, but have also characterized
glutamate signaling over a 24 time course.

While a consistent pattern of

glutamate signaling corresponding to changes in the circadian cycle did not
emerge, we did observe significant relationships between signaling parameters
during both the light and dark cycles of a 24 time period. These data indicate
that the circadian influence on infralimbic glutamate levels should not be
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considered a confound in future experiments, and the SCN may not exert a
strong impact on glutamatergic signaling in the infralimbic mPFC.
Copyright © Catherine Elizabeth Mattinson 2012
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Chapter Four: Figures
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Figure 4.1 24-Hour Glutamate Neurotransmission Signaling Parameters
24-hour traces of glutamate signaling parameters revealed significant effects. A
significant effect of time on glutamate resting levels (A; all animals averaged; p <
0.0001; n = 5) was found, and a significant effect of time on the number of
glutamate transients was also revealed (B; all animals averaged; p < 0.0001; n =
5).

There was also a significant effect of time on the transient peak amplitude

concentrations (C; all animals averaged; ***p < 0.001; n = 4). Individual traces of
each animal’s signaling parameters reveal heterogeneity among animals (D;
each color represents a different animal).
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Figure 4.2 Number of Glutamate Events and Concentration Correlate
The number of transient glutamate events was correlated to the concentration of
those glutamate events in both the light (A; R2 = 0.15; ***p < 0.001; n = 4) and
dark (B; R2 = 0.047; *p < 0.05; n = 4) portions of the 24-hour cycle. Each color
represents a different animal.
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Figure 4.3 Locomotor Activity Correlates with Glutamate Concentration During
the Light Cycle
When the distance traveled by an animal was correlated to the concentrations of
the glutamate peaks, a negative correlation was found during the light cycle (A;
R2 = 0.099; **p < 0.01; n = 5).

The dark cycle did not show a significant

correlation. Each color represents a different animal.
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Chapter Five: The Effects of Methylphenidate Treatment on Tonic
and Phasic Glutamate Levels in Sub-Regions of the Rat Medial
Prefrontal Cortex
Introduction
The mPFC is an area of the brain that is critically important for complex
cognitive processes including attention, memory, learning, organization, and
integration.

These processes are often interrupted or dysfunctional in the

development and maintenance of drug addiction. The abuse of stimulants in
particular may result in behavioral sensitization, a hypersensitivity caused by
repeated psychostimulant administration (Kalivas and Stewart 1991; Gaytan, alRahim et al. 1997; Dafny and Yang 2006). Thus, behavioral sensitization has
been proposed as a model of drug seeking (Robinson and Berridge 1993;
Hotsenpiller and Wolf 2002). Cocaine and amphetamine studies have implicated
the PFC in the development of behavioral sensitization (Pierce, Reeder et al.
1998; Tzschentke and Schmidt 1998; Cador, Bjijou et al. 1999; Li, Hu et al. 1999;
Liao and Lin 2008). Recently, Lee and colleagues also demonstrated that the
PFC was required for the development of behavioral sensitization associated
with MPH administration (Lee, Swann et al. 2008).
MPH is a stimulant drug that is commonly prescribed for the treatment of
attention-deficit hyperactivity disorder (Challman and Lipsky 2000; Swanson and
Volkow 2002; Askenasy, Taber et al. 2007). MPH has also been shown to have
abuse potential.

Rats will self-administer MPH (Botly, Burton et al. 2008;

Marusich and Bardo 2009; Marusich, Beckmann et al. 2010), and rats exposed to
MPH as adolescents will more readily adapt to cocaine administration as adults
(Brandon, Marinelli et al. 2001; Crawford, Baella et al. 2011; Harvey, Sen et al.
2011).
To further investigate the effects of an abused stimulant medication on the
mPFC, a high dose of MPH was chronically administered to rats.

After an

administration period and a rest period, glutamate was measured in three subregions of the mPFC: the cingulate cortex, the prelimbic cortex, and the
infralimbic cortex.

Glutamate is the major excitatory neurotransmitter in the
73

central nervous system, and mPFC glutamate is intimately associated with and
influenced by brain circuitry that is implicated in the development of drug
addiction. Stimulants such as cocaine and amphetamine have both been shown
to increase PFC glutamate (Reid, Hsu et al. 1997). Three sub-regions of the
mPFC were examined in an effort to detect any heterogeneous responses to
MPH treatment within the mPFC.
These experiments employed the use of MEA technology to measure both
tonic and phasic aspects of glutamate signaling in the mPFC. We hypothesized
that MPH would differentially affect glutamate neurotransmission in mPFC subregions. The improved spatial and temporal resolution of the MEA allowed for an
advanced characterization of resting glutamate levels and KCl-evoked glutamate
release in the three distinct sub-regions of the mPFC. Thus, we were able to
report, for the first time, the effects of MPH treatment on tonic and phasic
glutamate signaling in the mPFC.

Materials and Methods
Animals
Male Sprague-Dawley rats (Harlan, Indianapolis, IN) aged 3-6 months
were used for all experiments (n=11). For care, see Animals.

Methylphenidate Chronic Treatment
Chronic treatment of the rats with MPH prior to in vivo MEA recordings
was carried out by Dr. Julie Marusich of the University of Kentucky.

Rats

received daily MPH (10 mg/kg in saline, s.c.) or saline injections for ten
consecutive days. Following the ten day treatment period, rats rested for seven
days. Recordings were performed the day after the rest period (day 18 from the
start of the MPH injections).

Locomotor Monitoring
Activity monitoring was performed by Dr. Julie Marusich of the University
of Kentucky.

After receiving their daily injection, rats were placed in activity
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monitoring chambers for one hour. The distance traveled in centimeters was
averaged in five minute bins over the course of the hour, and then the bins were
averaged to obtain the average distance traveled per five minutes for each rat on
each day.

Microelectrode Preparation
MEAs for acute anesthetized recordings were made selective for
glutamate through enzyme coatings (see Microelectrode Array Configuration and
Preparation – Microelectrode Array Coatings), and an electroplated layer of mPD
(described in Microelectrode Array Configuration and Preparation – Exclusion
Layers). Prior to the experiment, in vitro calibrations (detailed in Microelectrode
Array Calibrations) were performed to determine the slope, selectivity, limit of
detection, and linearity of the MEAs. After calibration, a glass micropipette was
affixed to the MEA to allow for intracranial delivery of KCl (see Application of
Intracranial Solutions).

In Vivo Recordings
Acute anesthetized recordings were performed as previously described
(see Microelectrode Array Implantation Surgery and Recordings – Anesthetized
Surgery Procedures and – Anesthetized Recordings). On the day of surgery,
rats were anesthetized with urethane and the surgery was performed.

The

micropipette attached to the MEA was filled with an isotonic KCl solution (70 mM
KCl, 79 mM NaCl, 2.5 mM CaCl2 • 2H2O; pH = 7.4) and connected to a
Picospritzer III (Parker Hannifin Corp, NJ) to allow for local applications of KCl
into the extracellular space . The MEA/micropipette assembly was lowered into
the mPFC (AP: +3.2 mm; ML: ±0.8 mm; DV: -1.5 to -5 mm; from bregma
(Paxinos and Watson, 2009) using a Narishige MO-10 microdrive. The MEA
assembly was lowered in 0.5 mm increments and recordings were taken at each
depth to record glutamate levels along the dorsal-ventral axis of the mPFC. Once
lowered into place, basal levels were established over ten minute recording
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durations, and then KCl solution was ejected (75-100 nl) to evoke glutamate
release.

Histology
After the experiment, rats were euthanized under heavy anesthesia, and
microelectrode array placements were confirmed. For detailed procedures, see
Histology.

Data Analysis
Collected data were processed using a custom Matlab®-based analysis
package (Data Collection).

Data parameters analyzed were resting (tonic

release) glutamate levels (average of the ten data points prior to the first ejection
at each depth) and data from KCl-evoked release (phasic release) of glutamate
that included: peak amplitude, T80 (time for 80% of the signal to decay to
baseline), and k-1, best fit line of first order rate constant of the signal return to
baseline. Glutamate KCl-evoked peaks were volume matched (75-100 nL) for
data analysis. As data was not always attainable at every depth throughout the
depth profile due to clogging of the tips of the micropipettes, occasional data drop
out occurred.

For locomotor data, a two-tailed paired t-test was used for

analysis. Resting glutamate levels and phasic glutamate signaling parameters
were analyzed using both a one-way repeated measures ANOVA and individual t
tests. Significance was defined as p < 0.05.

Results
Methylphenidate Treated Rats Show Increased Locomotor Activity
After receiving their MPH or saline injections, rats were placed in
locomotor activity monitoring chambers to investigate the effects of treatment on
behavior.

Rats treated with MPH showed significant increases in distance

traveled as compared to saline controls (Figure 5.1; t(9) = 12; p < 0.0001). On
average, rats treated with MPH moved approximately 1200 cm more than their
saline treated counterparts within each five minute time bin.
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Resting Levels of Glutamate Are Similar Between Treatment Groups
When resting levels in the cingulate, prelimbic, and infralimbic cortex were
compared between rats chronically treated with MPH and their saline
counterparts, no significant differences were found (Figure 5.2). Both a one-way
repeated measures ANOVA (F(5,21) = 2.0; p = 0.12; saline, n = 4; MPH, n = 5)
and individual t tests were employed to check for significant differences between
the groups.

On average, the difference between the two treatment groups’

glutamate resting levels was 1.8 µM, although this difference was not significant.

Phasic Glutamate Signaling Shows Homogeneity in All Sub-Regions
Phasic glutamate signaling parameters including peak amplitudes, T80
values, and uptake rates were analyzed within each sub-region of the mPFC.
Peak amplitudes (Figure 5.2) did not differ significantly between MPH chronically
treated rats and saline controls in any of the three sub-regions explored (F(5,21)
= 0.30; p = 0.91; saline, n = 4; MPH, n = 5). T80 values were also found to be
similar among the three sub-regions and between the treatment groups (Figure
5.3; F(5,21) = 1.1; p = 0.40; saline, n = 4; MPH, n = 5). Uptake rates did not vary
significantly between the two treatment groups, nor among any of the subregions as well (Figure 5.3; F(5,21) = 0.44; p = 0.82; saline, n = 4; MPH, n = 5).
For a summary of these data, see Table 5.1.

Discussion
These studies, to our knowledge, are the first to characterize glutamate
signaling in the mPFC after chronic MPH treatment. The use of MEA technology,
with its advanced spatial resolution, allowed for measurements of glutamate in
distinct sub-regions of the mPFC in the same animal. The temporal resolution of
the MEA technology allowed us to detect second-by-second changes in KClevoked phasic glutamate signaling within the cingulate, prelimbic, and infralimbic
mPFC, thus revealing a more complete picture of dynamic changes in glutamate
neurotransmission. Our results reflect our previous work (Mattinson, Burmeister
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et al. 2011), with similar glutamate levels and signaling parameters among the
three sub-regions investigated.

Significant differences in locomotor behavior

existed between chronic MPH-treated and saline-treated groups, but no
differences in glutamate signaling existed.

Locomotor Effects of MPH Treatment
The behavioral effects of stimulant treatment are generally predictable,
and have been well established. Cocaine, methamphetamine, and amphetamine
were all shown to increase locomotor activity in mice in early studies (Dews
1953; Smith 1965), and Hughes and others reported increased motor activity
and rearing in rats receiving MPH (Hughes 1972; Bhattacharyya, Ghosh et al.
1980).

MPH administration increases extracelluar dopamine by blocking the

dopamine transporter (Ritz, Lamb et al. 1987; Heron, Costentin et al. 1994; Pan,
Gatley et al. 1994; Wayment, Deutsch et al. 1999), and this increase in
extracellular dopamine is thought to be responsible for increases in motor activity
(Rebec 2006). As lesion studies have shown, stimulant-induced increases in
locomotion are associated with these drugs’ effects on the mesolimbic
dopaminergic system, particularly in the nucleus accumbens (Kelly 1975; Joyce
and Koob 1981; Koob, Stinus et al. 1981). We also observed that over the ten
day treatment period, distance traveled increased an average of 1000 cm in the
MPH treated animals.

This increase in locomotor activity is consistent with

behavioral sensitization in response to chronic MPH treatment (Crawford,
McDougall et al. 1998; Yang, Amini et al. 2003; Wooters, Dwoskin et al. 2006;
Wooters, Bardo et al. 2011).

Thus, the increased locomotor behavior in

chronically MPH-treated rats in this study was as we anticipated. This increase
in activity served as a positive control, assured that the dose of MPH was
appropriate, and that the animals were responding as expected to the drug.
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Resting Levels of Glutamate Show Similarity Between Treatment
Groups
In these experiments, we examined the glutamate resting levels of
chronically MPH-treated rats and controls in three sub-regions of the mPFC.
Chronically MPH-treated rats averaged resting glutamate levels of 4.8 µM, 4.1
µM and 3.2 µM in the cingulate, prelimbic, and infralimbic mPFC, respectively. In
comparison, chronically saline-treated rats showed glutamate resting levels of
2.8 µM in the cingulate, 2.0 µM in the prelimbic, and 2.0 µM in the infralimbic. No
significant differences were found among mPFC brain sub-regions within each
treatment group. However, this information is consistent with our previous work
(Mattinson, Burmeister et al. 2011). Measurements of glutamate in the mPFC of
F344 rats revealed a homogeneity of glutamate resting levels among mPFC subregions. We have postulated that these similarities are due to uniform regulation
of tonic and phasic glutamate dynamics within the mPFC.
Our chronically saline-treated animals showed glutamate resting levels
that were increased by a minimum of 100% as compared to other reported
mPFC resting glutamate levels in Sprague-Dawley rats (Welty and Shoblock
2009; Roenker, Gudelsky et al. 2011). The difference in these glutamate resting
level concentrations can best be accounted for by the difference in technologies
used for measurement. Our reported concentrations of neurotransmitters in vivo
are often increased as compared to those concentrations obtained using
microdialysis (Hascup, Hascup et al. 2010). Our MEAs offer the advantage of
improved spatial resolution over microdialysis probes, allowing for measurements
of synaptic spill-over (Day, Pomerleau et al. 2006). Additionally, our probes have
been shown to cause minimal damage compared to microdialysis probes
(Hascup, af Bjerken et al. 2009), and only measure substances that come into
contact with the surface of the Pt recording site (Burmeister, Moxon et al. 2000).
Experiments in the mPFC of F344 rats (Mattinson, Burmeister et al. 2011)
revealed glutamate resting levels of 3.7 - 4.3 µM. These levels are increased as
compared to our glutamate resting levels in Sprague-Dawley rats from these
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experiments. As both sets of these experiments were performed under urethane
anesthesia and using MEA technology, the logical explanation for these
differences would be the strain of the animals. F344 rats are an in-bred strain
typically used for aging and cancer research (Cameron, Hickman et al. 1985),
whereas Sprague-Dawley rats are an out-bred strain commonly used in behavior
and drug studies.

Differences in genetics may account for the marked

differences in mPFC glutamate concentrations between these two strains.
Interestingly, the F344 levels are similar to the levels observed in our
Sprague-Dawley chronically MPH-treated rats.

Although chronically-MPH

treated rats do not vary significantly from the controls, the trend towards
augmented glutamate levels in the MPH treatment group is apparent.

An

increased n value could provide significant results. As MPH is known to increase
extracellular concentrations of dopamine (Hurd and Ungerstedt 1989; Butcher,
Liptrot et al. 1991), it is possible that increased concentrations of dopamine
within cortical and mesolimbic circuitry are responsible for potential increases in
glutamate release in the mPFC.
It should also be noted that urethane anesthesia was used in these
experiments, and Rutherford et al. has shown that urethane administration
significantly reduces resting levels of glutamate (Rutherford, Pomerleau et al.
2007). Thus, it is possible that our reported resting levels of glutamate in the
mPFC are actually significantly higher in both the MPH and saline treated groups
when urethane is not present, and further studies without the effects of
anesthetics are needed.

Dynamic Glutamate Signaling Parameters Are Homogenous
Dynamic glutamate signaling parameters including peak amplitudes, T80
values, and uptake rates were analyzed, and all parameters were found to be
similar between chronically MPH-treated and saline-treated groups, as well as
similar among mPFC sub-regions. Peak amplitudes (see Table 5.1) only varied
by 1.2 µM between the highest and lowest reported average values.

This

indicates that KCl-evoked glutamate release in all three mPFC sub-regions is
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relatively uniform. Additionally, MPH did not have an effect on stimulated phasic
glutamate release as compared to controls. This differs from previous work by
Stephans and Yamamoto (1995), who measured an increase in KCl-evoked
glutamate release in the mPFC after chronic administration of methamphetamine
(Stephans and Yamamoto 1995). As discussed in Chapter Three, microdialysis
studies have reported both an increase (Frantz, Harte et al. 2002) and no change
(Welty and Shoblock 2009) in mPFC glutamate levels in response to intracranial
KCl administration.

The rapid, phasic glutamate signal produced by KCl

ejections cannot be measured using microdialysis due to this technique’s poor
temporal resolution, and therefore, our results provide a better characterization of
KCl-evoked glutamate release in the mPFC.
Chronically MPH-treated rats’ T80 values in both the prelimbic and
infralimbic mPFC showed a trend toward increased time for 80% of signal decay
to occur.

These results were not significant, but the times averaged

approximately five and four seconds for the prelimbic and infralimbic,
respectively.

This increase in decay times may be due to drug-induced

differences in glutamate transporter dynamics (Danbolt 2001). Extinction from
cocaine administration has been shown to alter EAAT binding in the infralimbic
mPFC (Miguens, Crespo et al. 2008), however, acute and chronic amphetamine
administration has been shown to have no effect on EAAT levels in the PFC
(Sidiropoulou, Chao et al. 2001).

Additionally, although MPH has not been

shown to act on the glutamate transporter (Iversen 2006), it has been linked to a
down regulation of GLAST in the striatum (Cavaliere, Cirillo et al. 2012). Uptake
rates do not follow the same trend as T80 values, and remain relatively uniform
despite differing treatments and mPFC sub-regions.

Conclusions
From this set of experiments, we can conclude that chronically MPHtreated animals do not differ significantly from saline controls in both tonic and
phasic measurements of glutamate in the cingulate, prelimbic, and infralimbic
sub-regions of the mPFC. Although not significant, resting levels of glutamate
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trended towards increased glutamate concentrations in chronically MPH-treated
rats in all mPFC sub-regions, and a trend of increased T80 values in the prelimbic
and infralimbic mPFC of chronically MPH-treated rats was observed. Further
experiments are needed to discern whether these trends are potential sources of
significant differences. We did find, as predicted, significantly increased amounts
of locomotor activity in animals chronically treated with MPH as compared to
saline controls. Future experiments in awake freely-moving animals would allow
for the simultaneous comparison of MPH treatment and animal behavior, thus
providing a better characterization of the effects of MPH treatment on glutamate
signaling in the mPFC.

Copyright © Catherine Elizabeth Mattinson 2012
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Chapter Five: Figures
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Figure 5.1 Locomotor Activity Following Methylphenidate Treatment
After the daily treatment injection, rats were placed in locomotor chambers for
one hour (saline, n = 4; MPH, n = 5). Distance traveled in five minute bins was
averaged for each rat on each day. Rats treated with MPH had significantly
increased locomotor activity as compared to the saline controls (t(9) = 12; ****p <
0.0001; two-tailed paired t test). Data points are shown as averages ± SEM.
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Figure 5.2 Glutamate Resting Levels and Peak Amplitudes in Prefrontal Cortex
Sub-Regions
Analyses of resting levels of glutamate levels (A) revealed similar concentrations
between treatment groups and among sub-regions (saline, n = 4; MPH, n = 5).
Peak amplitude measurements (B) were also fairly homogenous.
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Figure 5.3 GlutamateT80 Values and Uptake Rates in Medial Prefrontal Cortex
Sub-Regions
Both T80 values (A) and uptake rates (B) showed homogeneity between chronic
treatment groups and among sub-regions (saline, n = 4; MPH, n = 5).
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Table 5.1 Comparison of Glutamate Signaling Parameters Between MPH
Treated Rats and Controls
Brain

Chronic

Sub-Regions Treatment
Cg1

PrL

IL

Peak Amplitudes T80 Values Uptake Rates
(µM)

(s)

(µM /s )

Saline

2.6 ± 2.7

2.5 ± 0.56

1.7 ± 1.4

MPH

2.4 ± 1.9

3.0 ± 1.4

1.1 ± 1.3

Saline

2.9 ± 1.7

4.9 ± 2.6

0.80 ± 0.47

MPH

2.0 ± 1.6

2.9 ± 1.3

0.89 ± 1.9

Saline

2.0 ± 0.71

4.0 ± 3.1

2.1 ± 2.7

MPH

1.7 ± 1.3

2.6 ± 1.6

1.2 ± 0.92

Phasic glutamate signaling parameters of peak amplitudes, T80 values, and
uptake rates show similarity between the treatment conditions in each mPFC
sub-region (mean ± SD; saline, n = 4; MPH, n = 5).
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Chapter Six: The Effects of Methylphenidate on Infralimbic
Prefrontal Cortex Glutamate Signaling in the Awake Freely-Moving
Rat
Introduction
MPH is a stimulant medication that used in the treatment of attentiondeficit hyperactivity disorder. As a stimulant, MPH is also abused, particularly in
the adolescent and college age populations (DeSantis, Webb et al. 2008;
Dupont, Coleman et al. 2008; Bogle and Smith 2009; Setlik, Bond et al. 2009). It
has been reported that approximately 20% of children and adolescents taking
MPH have been approached to sell, give away or trade their medication (Musser,
Ahmann et al. 1998; Kollins, MacDonald et al. 2001). Additionally, in human
discriminative-stimulus studies, MPH has been shown to produce high levels of
amphetamine- and cocaine-appropriate responding (Heishman and Henningfield
1991; Rush, Kollins et al. 1998; Rush and Baker 2001), highlighting the subjectperceived similarity between MPH and known stimulants of abuse.
The infralimbic mPFC was chosen as the site of interest in these studies
because of its involvement in drug addiction.

The infralimbic sub-region

specifically has been shown to be critical for suppressing drug seeking behavior
following extinction in rats (Peters, LaLumiere et al. 2008; Peters, Kalivas et al.
2009; LaLumiere, Smith et al. 2012). Additionally, data from our anesthetized
chronic MPH treatment studies suggest that the infralimbic mPFC may be an
area that differs in glutamate signaling parameters such as resting glutamate
levels and T80 (time for 80% of a phasic signal to decay to baseline) between
chronically MPH-treated and saline-treated rats.

Rapid, transient glutamate

events (Hascup, Hascup et al. 2011) were also examined, as our advanced MEA
technology offers the ability to sample glutamate signaling on a sub-second time
scale.
Our earlier work sought to characterize the effects of MPH on glutamate
signaling in three sub-regions of the mPFC through a depth profile analysis. To
gain further insight into the effect of MPH on infralimbic glutamatergic
transmission without the confound of anesthesia, we chronically treated rats with
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MPH, implanted MEAs in the infralimbic mPFC for glutamate detection, and
recorded glutamatergic neurotransmission and behavior during an MPH
challenge dose and a cocaine challenge dose. The challenge dose paradigm
was used to investigate the possibility of sensitization to MPH following chronic
treatment and a rest period, as it has been shown that behavioral responses to
psychomotor stimulants exist long after drug treatment (Pierce and Kalivas
1997). Thus, we hypothesized that we would see behavioral sensitization, as well
as a sensitization of tonic and phasic glutamate signaling to MPH administration.

Materials and Methods

Animals
Male Sprague-Dawley rats, aged 3-6 months were used for these
experiments (for care, see Animals). Following MEA implant surgery, animals
were monitored and weighed daily. If an animal weighed less than 80% of its
pre-surgery body weight, recordings were not performed that day.

Methylphenidate Administration
Rats received injections for ten consecutive days. Animals were injected
with either MPH (10 mg/kg in saline; s.c.) or saline (s.c.), and then placed in a
locomotor activity monitoring chamber for one hour.

Following activity

monitoring, animals were given saline injections (s.c.) before being returned to
their home cages.

Locomotor Activity Monitoring
After receiving the initial MPH or saline injection, animals were placed in a
Digiscan animal activity monitoring device inside of the recording chamber.
Multiple parameters of locomotion, including distance traveled and number of
movements, were measured in five minute time bins over the course of one hour
using Oasis software. Locomotor activity was measured for the entire duration of

88

electrochemical recording sessions.

After a recording session, the recording

chamber was cleaned with Roccal disinfectant (Pfizer, Inc., New York City, NY).

Experimental Timeline
The total length of each experiment was 20 days. Animals received either
MPH or saline injections for ten consecutive days, and then were given a seven
day rest period. During the rest period, on day 14 of the experiment, MEAs were
implanted. Animals were given 3 days to recover from surgery before recordings
were started. Recordings were performed on day 18, when rats received a MPH
challenge dose, and on day 20, when they received a cocaine challenge dose.
After the last recording, animals were euthanized and brains were collected.

Microelectrode Array Preparation
To optimize the MEA for chronic recordings, the MEA circuit board was
minimized, and the MEA was epoxied to a plug/connector assembly
(Microelectrode Array Configuration and Preparation – Modifications for Awake
Freely-Moving Recordings). MEAs were made selective for glutamate through
the use of glutamate oxidase coating layers (Microelectrode Array Configuration
and Preparation – Microelectrode Array Coatings).

For in vivo chronic

recordings, Nafion® was used as the exclusion layer (Microelectrode Array
Configuration and Preparation – Exclusion Layers) to prevent electroactive
interferents from coming into contact with the Pt recording sites.

Prior to

implantation, MEAs were calibrated in vitro (Microelectrode Array Calibrations).
For awake freely-moving MEAs, the calibrations were performed within the
recording chamber to best simulate the environment in which the recordings
would take place. After calibration, MEA ceramic tips and reference electrodes
were soaked in phosphate buffered saline (PBS; 0.05 M) until the implantation
surgery.
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Microelectrode Array Implant Surgery
MEA implant surgery procedures are described in Microelectrode Array
Implant Surgery and Recordings – Awake Freely-Moving Surgery Procedures.
Surgical tools were autoclaved for the first surgery of the day, and sterilized in a
glass bead sterilizer for any subsequent surgeries. Total time for each surgery
was approximately one hour.

Awake Freely-Moving Recordings
All recordings were performed at 4 Hz. For details regarding recording
protocols, see Microelectrode Array Implant Surgery and Recordings – Awake
Freely-Moving Recordings. On day 18 of the experiment, rats were connected to
their tethers outside of the recording chambers, in their home cages.

This

allowed for the signal to baseline before injections and placement into the
recording chamber.

After approximately one hour of baseline, the rats were

given a saline injection and placed in the recording chamber. At this point, the
activity monitoring software was also started.

One hour following the saline

injection, rats in both groups were given MPH challenge doses (10 mg/kg, s.c.).
Recordings were performed for three hours following the challenge dose
injections.

Animals were monitored during the recordings, and if the tether

became tangled due to locomotor activity, the experimenter unobtrusively
unwound the line using the swivel. At the end of the experiment, animals were
returned to their home cages.
On day 20, similar procedures were followed for a cocaine challenge.
Both the saline injection and cocaine injection (10 mg/kg) were given i.p.
Recordings were only continued for 90 minutes after the cocaine challenge
injection, due to the shorter half-life of cocaine. After the experiments, animals
were returned to their home cages, and then later sacrificed.

Histology
After the experiments, animals euthanized under heavy anesthesia and
their brains were removed to check for MEA placements.
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For details, see

Histology. Animals with MEA placements outside of the infralimbic cortex were
excluded from data analysis.

Data Analysis and Statistics
Collected data were processed using a custom Matlab®-based analysis
package (Data Collection). Data parameters of interest included resting levels of
glutamate, glutamate peak amplitudes, T80 values, and uptake rates. To examine
phasic glutamate activity, recordings were scanned using a peak finder tool with
a threshold set at a minimum of a signal-to-noise ratio of 2.5.

A two-way

repeated measures ANOVA was used for data analysis, with a Bonferroni post
hoc test. Data points more than two standard deviations away from the mean
were excluded from analyses. Significance was defined as p < 0.05.

Results
Chronic Treatment with Methylphenidate Increases Locomotor Activity
After receiving a daily injection of either MPH (n = 9) or saline (n = 8),
animals’ locomotor activity was monitored.

Significant effects were found in

distance traveled (Figure 6.1) including effects of time (F(9,15) = 1.96; p = 0.050)
and treatment with MPH (F(1,15) = 110; p < 0.0001), and an interaction was also
found to be significant (F(9,135) = 4.1; p = 0.0001). The number of movements
(Figure 6.1) also showed significant effects of time (F(9,15) = 2.8; p = 0.0047)
and treatment with MPH (F(1,15) = 26; p = 0.0001).

Saline Injections Before Challenge Doses Reveal Significant Effects
On drug challenge days, saline injections were administered prior to the
MPH or cocaine injections. On MPH challenge days, saline injections showed a
significant effect of time on distance traveled (Figure 6.2; F(5,12) = 15; p =
0.0001; n = 7), while no effects were seen in number of movements (Figure 6.2).
On cocaine challenge days, saline injections also showed a significant effect of
time (Figure 6.8; F(5,12) = 5.8; p = 0.0002; n = 7). Similar to MPH challenge
days, no effects were seen in the number of movements (Figure 6.8).
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Resting levels of glutamate following these saline injections were also
analyzed.

On MPH challenge days, resting levels of glutamate showed a

significant effect of time (Figure 6.3; F(7,11) = 2.3; p = 0.037; saline, n = 6; MPH,
n = 7), and on cocaine challenge days, resting levels of glutamate showed a
significant interaction (Figure 6.9; F(7,84) = 2.6; p = 0.017; n = 7) as well as a
significant effect of time (F(7,12) = 2.8; p = 0.011).
Glutamate signaling parameters including number of peaks, peak
amplitude, T80 values, and uptake rates were calculated for saline injections on
drug challenge days. Following saline injections on MPH challenge days, none
of the parameters of interest showed significant effects, indicating a relative
uniformity of data (Figure 6.4). On cocaine challenge days, saline injections
resulted in a significant effect of time on number of glutamate peaks (Figure 6.10;
F(7,12) = 2.5; p = 0.023; n = 7). There were no effects in peak amplitudes, T80
values, or uptake rates following saline injections on cocaine challenge days.

Methylphenidate Challenge Dose Affects Locomotor Activity, Glutamate
Resting Levels, and Phasic Glutamate Signaling
When MPH was administered as a challenge dose, significant effects
were found in both measures of locomotor activity (Figure 6.5).

Significant

effects of time (F(31, 12) = 18; p < 0.0001; n = 7) and chronic treatment (F(1,12)
= 5.5; p = 0.038) were shown, and a significant interaction was also present
(F(31, 372) = 5.1; p < 0.0001) for distance traveled. Number of movements also
displayed significant effects of time (F(31,12) = 4.4;p < 0.0001; n = 7) and chronic
treatment (F(1,12) = 9.3; p = 0.010).
The significance found in resting levels of glutamate after MPH challenge
dose injection includes an effect of time (Figure 6.6; F(31,12) = 7.5; p < 0.0001; n
= 7) and an interaction (F(31, 372) = 4.2; p < 0.0001).
Uptake rates of phasic glutamate signaling associated with an MPH
challenge dose showed a significant interaction (Figure 6.7; F(31, 341) = 1.6; p =
0.026; saline, n = 6; MPH, n = 7). No significant effects or interactions were
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found for the number of glutamate peaks, peak amplitudes, and T80 values. A
two-way repeated measures ANOVA was used for all analyses.

Significant Effects Seen in Locomotor Activity, Glutamate Resting Levels,
and Peak Amplitudes Following Cocaine Challenge Dose
The administration of a cocaine challenge dose resulted in significant
effects of time on both distance traveled (Figure 6.11; F(19,12) = 3.4; p < 0.0001;
n = 7) and number of movements (F(19,12) = 2.9; p < 0.0001) over 90 minutes.
Glutamate resting levels showed a significant interaction (Figure 6.12;
F(19, 228) = 4.0; p < 0.0001; n = 7) associated with the cocaine challenge dose.
Phasic glutamate signaling parameters including number of peaks, peak
amplitudes, T80 values, and uptake rates (Figure 6.13) did not show any
significant effects or interactions with the cocaine challenge dose. A two-way
repeated measures ANOVA was used for all analyses.

Discussion
This set of experiments illustrates the effects of chronic MPH treatment on
locomotor behavior and glutamate signaling in the infralimbic sub-region of the
prefrontal cortex.

These studies reveal, for the first time, the in vivo

glutamatergic response to MPH in the awake freely-moving animal. Challenge
doses of MPH and cocaine were used to gain insight into possible behavioral or
pharmacological sensitization that may have occurred following chronic treatment
with MPH. Data indicated the presence of behavioral sensitization (see Chapter
5) during the chronic MPH treatment period, and revealed significant effects in
locomotor behavior and glutamate resting levels following saline injections, MPH
injections, and cocaine injections.

Chronic MPH Treatment Significantly Increases Locomotor Activity
Animals were treated with an abuse-level dose of MPH for ten days as a
chronic treatment period.

During this time, animals receiving MPH showed

consistently increased levels of locomotor activity. As previously discussed in
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Chapter 5, stimulant drugs predictably produce increased amounts of locomotor
activity following administration (Dews 1953; Smith 1965; Hughes 1972;
Bhattacharyya, Ghosh et al. 1980), and this is attributable to the behavioral
sensitization associated with stimulant drug administration.

It should be noted

that on day 1 of treatment, both chronically MPH-treated and saline-treated
animals showed similar numbers of movements. As the number of movements
decreased and remained stable for chronically saline-treated rats, it can be
assumed that the increase in locomotor activity was most likely due to exploring
a novel environment.

Saline Control Injections Are Associated with Significant Effects on
Locomotor Activity and Glutamate Resting Levels
After the chronic treatment period and the subsequent rest period, animals
were given a control saline injection one hour prior to their MPH or cocaine
challenge doses. Animals were connected to their tethers while in their home
cages outside of the recording chamber to ensure that the glutamate signal had
time to baseline before any pharmacological manipulations took place. After the
baseline period, rats received saline injections and were placed in the recording
chamber.
Both chronically MPH-treated and saline-treated animals showed similar
significant effects of time on locomotor activity after the saline injection on day
18, the MPH challenge dose day. These patterns of locomotor activity between
the two groups were surprisingly similar. Both groups of animals started with
distance traveled total of around 1500 cm that decreased to approximately 500
cm, with similar slopes, over the course of 30 minutes.

As the response of the

chronically MPH-treated animals closely matched that of the chronically salinetreated animals, we can conclude that the injection and subsequent placement in
the recording chamber did not lead to the behavior sensitization response
previously seen in the MPH-treated animals during their chronic treatment period.
On day 20, prior to cocaine administration, a saline injection was administered
and resulted in locomotor levels slightly less than the saline injections given on
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day 18.

It should be noted that this was the animals’ first exposure to an i.p.

injection, and this may account for the decreased levels of locomotion as
compared to day 18.
Resting levels of glutamate were recorded from the infralimbic mPFC
during the saline injection administration on both MPH and cocaine challenge
dose days. On day 18, the s.c. saline injection resulted in a significant effect of
time. Chronically MPH-treated animals averaged glutamate resting levels of 14
µM, and chronically saline-treated animals averaged glutamate resting levels of
22 µM following the saline injection.

Other groups have reported glutamate

resting level concentrations ranging from 0.15 to 1.0 µM in the mPFC of awake
freely-moving Sprague-Dawley rats (Yamamoto and Cooperman 1994; Welty
and Shoblock 2009; Roenker, Gudelsky et al. 2011). The more than 20-fold
difference between our chronically saline-treated animals’ resting levels of
glutamate and the levels of these microdialysis studies can best be explained by
the advanced spatial resolution of our MEAs.

The possibility of the saline

injection itself or the change in environment from home cage to recording
chamber being the reasons for the increased resting levels as compared to the
microdialysis studies does not seem probable, as glutamate resting levels did not
change significantly from pre-injection glutamate resting levels.

The 38%

decrease in resting levels of glutamate of the chronically MPH-treated rats as
compared to saline controls is not what we would have anticipated based on our
anesthetized results (see Chapter 5). As the resting levels of glutamate of the
chronically MPH-treated rats did not change significantly following the saline
injection, it appears that the decrease in resting levels may be due to long term
effects of chronic MPH treatment. In other stimulant literature, cocaine has been
shown to significantly decrease mPFC glutamate levels during self-administration
of the drug, while increasing dopamine levels (Ben-Shahar, Szumlinski et al.
2012), and amphetamine has been shown to decrease excitatory glutamatergic
transmission in the PFC (Mair and Kauer 2007).

Therefore it has been

hypothesized that increased dopamine levels may be responsible for decreasing
glutamate release via activation of D1 receptors in the mPFC (Abekawa, Ohmori
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et al. 2000; Mair and Kauer 2007). Additionally, MPH administration has been
shown to significantly decrease synaptic active zone length in the PFC and alter
GLAST levels in the striatum (Cavaliere, Cirillo et al. 2012). Thus, it could also
be possible that alterations in GLT-1 and GLAST in the mPFC are responsible for
the observed decreased glutamate resting levels. Taken together, these findings
provide support for our observed decrease in resting glutamate levels in
chronically MPH-treated rats.
The saline injection given prior to the cocaine challenge dose on day 20
showed similar results to that of the saline injection given on day 18.

The

glutamate resting levels of the chronically MPH-treated rats were comparable to
those observed on day 18.

The significant effect of time is evident in the

decrease in resting levels of glutamate of the chronically saline-treated rats,
which were attenuated from 28 µM to 22 µM over the 30 minute time period.
This decrease in resting levels associated with the saline injection may be due to
the first exposure to an i.p. injection, which would cause stress to the animal.
This injection was also the first injection following their previous exposure to
MPH.

Thus, the decrease in glutamate resting levels may be a sign of

sensitization to the effects of the MPH injection. Additionally, a significant
interaction was observed, indicating that there is a complex relationship between
chronic treatment and time. Chronic treatment and time serve as independent
variables that work together to produce effects on our measurements of
glutamate resting levels.
Parameters of phasic glutamate signaling did not show any significant
differences following the saline injection on day 18, although a significant effect
of time on number of glutamate peaks or transients existed on day 20. This is
not surprising, given our anesthetized data.

Thus, it appears that the saline

injections were not capable of influencing dynamic glutamate signaling in the
mPFC, although they did affect tonic glutamate signaling.
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MPH Challenge Injection
The administration of the MPH challenge dose resulted in significant
effects of time and chronic treatment in both distance traveled and number of
movements, with a significant interaction also present for distance traveled. The
sensitized locomotor response to our MPH challenge injection from the
chronically MPH-treated animals was apparent in the distance traveled within the
first hour following the injection. Within sixty minutes, we observed increased
levels of motor activity in the chronically MPH-treated group as compared to the
chronically saline-treated control group, followed by a plateauing of distance
traveled by the chronically MPH-treated group and a dramatic increase in
distance traveled by the chronically saline-treated group.

The locomotor

sensitization seen in the chronically MPH-treated group of animals supports the
previous findings that stimulants can induce behavioral sensitization. However,
the chronically saline-treated animals achieved amounts of distance traveled
higher than those of the chronically MPH-treated animals during their chronic
treatment period, as well as during the MPH challenge dose. This result was
unexpected, given that the chronically saline-treated animals were drug naïve
until this MPH administration.
The resting levels of glutamate of the chronically MPH-treated rats
following the MPH injection remained relatively constant and did not vary from
pre-injection levels. Following the MPH injection, chronically saline-treated rats
showed a marked decrease in glutamate resting levels that approached the
levels of the chronically MPH-treated rats after approximately two hours. As
MPH increases dopamine levels, this decrease in glutamate resting levels could
be attributed to dopamine hyperactivity stimulating D1 receptors.
Dynamic glutamate signaling did not show significant effects following
MPH administration, except in the case of uptake rates which showed a
significant interaction. It appears from our results that MPH administration acts
on resting glutamate levels more so than phasic aspects of glutamate signaling.
This makes sense in light of second messenger systems involved in D1 receptor
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activation, which would lack the temporal resolution needed to induce changes in
rapid, phasic glutamate signaling.

Cocaine Challenge Injection
Following cocaine injection administration, significant effects of time were
seen in both distance traveled and number of movements, and behavioral
sensitization was evident in the chronically MPH-treated animals in distance
traveled.

Twenty minutes after cocaine injections, chronically MPH-treated

animals peaked in distance traveled as compared to their saline counterparts. In
addition to behavioral sensitization, this is an example of cross sensitization, the
increase in locomotor activity that occurs when treatment with one substance (in
this case, MPH) leads to sensitization effects when another substance is
presented (in this case, cocaine) (Aizenstein, Segal et al. 1990).

Cross

sensitization has been well documented in numerous cases among MPH and
other drugs of abuse (Schenk and Izenwasser 2002; Yang, Swann et al. 2003;
Valvassori, Frey et al. 2007; Wooters, Neugebauer et al. 2008; Wanchoo, Swann
et al. 2009). Cross sensitization experiments are essential for understanding the
likelihood of the use and/or abuse of one drug leading to the abuse of another.
Resting levels of glutamate after cocaine administration showed a
significant interaction, with chronically MPH-treated animals showing a slight
increase in resting levels, and chronically saline-treated animals showing a
decrease in resting levels. The decrease in resting levels could once again be
account for by D1 activation, but the increase in glutamate resting levels in the
chronically-MPH treated group show the opposite effect.

There has been a

report of amphetamine increasing glutamate levels in the mPFC (Del Arco,
Martinez et al. 1998), but this effect was not seen previously with the MPH
challenge dose on day 18. It could be that with the shorter half-life of cocaine as
compared to MPH, we recorded long enough to see resting levels begin to return
to levels closer to those of the chronically saline-treated animals.
Once again, no significant differences in dynamic glutamate signaling
parameters were observed. If the animals had received injections, and then
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performed a task, it is possible that we may have observed differences between
chronically MPH- and saline-treated animals, as the infralimbic mPFC has been
implicated in working memory and extinction. Thus, future experiments should
include a task component to allow us to better characterize chronic treatment
effects on phasic signaling during goal-directed behavior.

Conclusions
This set of experiments sought to characterize glutamate signaling in the
awake freely-moving animal following chronic treatment and subsequent
challenge with MPH. Our results suggest that MPH increases locomotor activity,
in accordance with previous studies.

Additionally, chronic MPH treatment

resulted in decreased resting levels of glutamate, and following MPH
administration, the resting levels of chronically saline-treated animals attenuated
to levels similar to the chronically MPH-treated animals.

This observation

provides support for the hypothesis that increased dopamine levels lead to D1
activation and subsequent glutamate suppression in the mPFC. For the majority
of the experiments, we did not observe differences in dynamic signaling
parameters. This may be due to the fact that we did not employ a task that
would require rapid glutamate neurotransmission, and thus we did not see
differences between the chronic treatment groups. Overall, this data suggests
that the glutamate system should not be overlooked in stimulant abuse studies,
particularly in the infralimbic mPFC. Further work examining the relationships
between glutamate and dopamine signaling in the infralimbic mPFC are needed
to fully understand the neurochemical changes associated with drug addiction.
The studies in this chapter provide a possible target for the therapeutic treatment
of drug addiction.

Copyright © Catherine Elizabeth Mattinson 2012
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Chapter Six: Figures
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Figure 6.1 Locomotor Activity During Chronic Treatment Period
During the ten day treatment period, rats that received MPH injections (n = 9)
showed significantly increased distance traveled (A; ***p < 0.001) and number of
movements (B) as compared to saline controls (n = 8). Both sets of data were
analyzed with a two-way repeated measures ANOVA. Data shown are mean ±
SEM.
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Figure 6.2 Motor Activity Decreases After Saline Injection on MPH Challenge
Day
After receiving a saline injection (blue arrow) and being placed into the recording
chambers, both MPH and saline treated rats (n = 7) showed a significant effect of
time during distance traveled (A; ***p < 0.001). There were no differences in the
number of movements following the injection (B). Data were analyzed with a
two-way repeated measures ANOVA. Data are shown as mean ± SEM.
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Figure 6.3 Glutamate Resting Levels Show A Significant Effect of Time After
Saline Injection on MPH Challenge Day
Resting levels of glutamate (saline, n = 6; MPH, n = 7) were measured following
a saline injection (blue arrow), and analysis revealed a significant effect of time
(*p < 0.05). Data were analyzed using a two-way repeated measures ANOVA.
Data are shown as mean ± SEM.
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Figure 6.4 Phasic Glutamate Signaling Following Saline Injections on MPH
Challenge Day
The number of peaks (A), peak amplitudes (B), T80 values (C), and uptake rates
(D) were examined for both MPH and saline treated rats (saline, n = 6; MPH, n =
7) following a saline injection (blue arrow). No significant differences were found.
Data were analyzed using a two-way repeated measures ANOVA. Data are
shown as mean ± SEM.
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Figure 6.5 Methylphenidate Injections Result in Increased Locomotor Activity
After the administration of MPH injections (green arrow), significant effects of
time (***p < 0.001), chronic MPH treatment (p < 0.05), and an interaction (p <
0.001) were seen in the amount of distance traveled (A; n = 7). The number of
movements (B) shows significant effects of time (***p < 0.001) and chronic MPH
treatment (p < 0.05). Data were analyzed using a two-way repeated measures
ANOVA. Data are shown as mean ± SEM.
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Figure 6.6 Glutamate Resting Levels Following MPH Injections
MPH injections (green arrow) resulted in a significant interaction (***p < 0.001)
and a significant effect of time (***p < 0.001) between glutamate resting levels of
saline and MPH treated rats (n = 7).

Data were analyzed using a two-way

repeated measures ANOVA. Data are shown as mean ± SEM.
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Figure 6.7 Phasic Glutamate Signaling Following MPH Injections
Following MPH injections (green arrow), rats displayed relatively homogenous
numbers of peaks (A), peak amplitudes (B), and T80 values (C) in both saline and
MPH treated groups (saline, n = 7 for number of peaks and peak amplitudes, n =
6 for T80 values and uptake rates; MPH, n = 7).

There was a significant

interaction for uptake rates (D; *p < 0.05). Data were analyzed using a two-way
repeated measures ANOVA. Data are shown as mean ± SEM.
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Figure 6.8 Locomotor Activity Following Saline Injections on Cocaine Challenge
Day
On the cocaine challenge day, saline and MPH treated rats (n = 7) were injected
with saline (yellow arrow).

Data revealed a significant effect of time (***p <

0.001) on distance traveled (A) after the injection. This time effect was not seen
in number of the animals’ movements (B). Data were analyzed using a two-way
repeated measures ANOVA. Data are shown as mean ± SEM.
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Figure 6.9 Glutamate Resting Levels Following Saline Injections on Cocaine
Challenge Day
Saline injections (yellow arrow) administered before the cocaine challenge
resulted in a significant interaction (*p < 0.05) and a significant effect of time (*p <
0.05) on glutamate resting levels in rats (n = 7). Data were analyzed using a twoway repeated measures ANOVA. Data are shown as mean ± SEM.
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Figure 6.10 Phasic Glutamate Signaling After Saline Injections on Cocaine
Challenge Day
A significant effect of time was seen in the number of peaks (A; *p < 0.05; n = 7)
following saline injections (yellow arrow).

Other phasic glutamate signaling

parameters such as peak amplitudes (B; n = 7), T80 values (C; saline, n = 7;
MPH, n = 6), and uptake rates (D; saline, n = 7; MPH, n = 5) did not reach
significance. Data were analyzed using a two-way repeated measures ANOVA.
Data are shown as mean ± SEM.
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Figure 6.11 Locomotor Activity Following Cocaine Injections
Following cocaine injections (purple arrow), significant effects of time (***p <
0.001) were observed for both distance traveled (A) and number of movements
(B; n = 7). Data were analyzed using a two-way repeated measures ANOVA.
Data are shown as mean ± SEM.
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Figure 6.12 Tonic Glutamate Levels Following Cocaine Injections
A significant interaction (****p < 0.001; n = 7) was seen in resting glutamate
levels following cocaine injections (purple arrow). Data were analyzed using a
two-way repeated measures ANOVA. Data are shown as mean ± SEM.
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Figure 6.13 Phasic Glutamate Signaling After Cocaine Injections
Following cocaine injections (purple arrow), no significant effects were observed
in the number of peaks (A; n = 7), peak amplitudes (B; n = 7), T80 values (C;
saline, n = 7; MPH, n = 6) or uptake rates (D; saline, n = 7; MPH, n = 5). Data
were analyzed using a two-way repeated measures ANOVA. Data are shown as
mean ± SEM.
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Chapter Seven: Final Conclusions
There is a lack of understanding of glutamate neurochemistry in the
medial prefrontal cortex (mPFC), despite the critical role that this brain structure
plays in higher cognitive processes and neuropathologies. Initially, this body of
work characterized glutamatergic signaling in the mPFC, and from our mapping
studies, we found that glutamate levels in the cingulate, prelimbic, and infralimbic
mPFC were relatively uniform, as were ACh levels in these three sub-regions.
The similarity in glutamate and ACh neurotransmission within the mPFC
underscores a somewhat homogenized regulation of the glutamatergic and
cholinergic systems in this brain area.
Our awake freely moving studies in the infralimbic mPFC did not find
evidence of circadian effects on glutamate signaling. However, we did establish
relationships between glutamate signaling parameters and locomotion during the
light and dark cycles of the circadian cycle. Importantly, we observed rapid and
dynamic glutamate transients. These findings support other recent studies that
have reported this aspect of phasic glutamate signaling (Hascup, Hascup et al.
2011; Wassum, Tolosa et al. 2012)
Our second mapping study looked at the effects of chronic MPH treatment
on glutamate signaling in the mPFC, and did not find that the drug had any
significant effect on glutamate resting levels or glutamate signaling parameters.
Locomotor monitoring did reveal behavioral sensitization, which is thought to
model drug-induced plasticity. Due to the effects of anesthesia on glutamate
resting levels, we then carried out this experiment, with a challenge dose
paradigm, in the awake freely-moving animal.
The final study explored the effects of a challenge stimulant dose on
glutamate neurotransmission following chronic MPH treatment in the awake
freely-moving rat. Once again, locomotor behavioral sensitization was observed
during the chronic treatment period in MPH-treated animals, and we confirmed
the presence of glutamate transients.
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Significant effects were observed in

glutamate resting levels, although most other glutamate signaling parameters did
not show significance. From our data, it appears that chronic MPH treatment
resulted in decreased glutamate resting levels, and the MPH challenge dose
given to chronically saline-treated animals decreased resting glutamate
concentrations to similar levels.
Taken together, this set of experiments provides data on mPFC glutamate
signaling to a degree never before reported, and also advances our
understanding of the effects of chronic MPH treatment on glutamate signaling in
the mPFC. This is the first report of mPFC sub-regional levels of glutamate and
ACh using MEA technology, thus providing insight into neurotransmission in the
discreet areas of a complex brain structure involved in many aspects of cognitive
functioning. Additionally, the characterization of the effects of MPH on glutamate
signaling in the mPFC eliminate the paucity of information regarding the actions
of this drug of abuse on excitatory neurochemistry in a brain region implicated in
higher cognitive processes.
With the information gained from our studies, scientists have an additional
source of in vivo glutamate concentration levels in the mPFC, as measured using
MEA technology. It is our hope that these data will provide insight into typical
glutamate neurotransmission, as well as glutamate neurotransmission under the
chronic influence of a drug of abuse.

This information can be used to help

develop pharmacotherapies that target the glutamatergic system and improve the
lives of drug addicts.
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